CHARTERED ACCOUNTANTS CHARTERED ACCOUNTANTS

Independent Auditor's Report on Restated Consolidated Financial Statements

То

The Board of Directors Chandan Healthcare Limited Biotech Park, Sector G, Kursi road, Jankipuram Lucknow, Uttar Pradesh, India, 226021


Dear Sir,

1. We have examined the attached restated consolidated financial information of CHANDAN HEALTHCARE LIMITED (hereinafter referred to as "the Company") and its subsidiaries (the Company and its subsidiaries collectively referred to as the "Group") comprising the Restated Consolidated Statement of Assets and Liabilities as at March 31, 2024, March 31, 2023 and March 31, 2022, the Restated Consolidated Statements of Profit and Loss, the Restated Consolidated Cash Flow Statement for the year ended March 31, 2024, March 31, 2023, March 31, 2022, the Statement of Significant Accounting Policies and the Notes as forming part of these Restated Consolidated Financial Statements (collectively, the "Restated Consolidated Financial Information"), as approved by the Board of Directors of the Company at their meeting held on 12th September, 2024, for the purpose of inclusion in the Red Herring Prospectus/ Prospectus("Offer Document") prepared by the Company in connection with its proposed SME Initial Public Offer.

These Restated Summary Statements for offer of equity shares ("SME IPO") has been prepared in accordance with the requirements of:

- sub-clauses (i) and (iii) of clause (b) of sub-section (1) of section 26 of part I of chapter III of the Companies Act, 2013 including Rules thereon, as amended ("the Act") read with Companies (Prospectus and Allotment of Securities) Rules 2014;
- (ii) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2018, as amended ("ICDR Regulations") and related amendments / clarifications from time to time issued by the Securities and Exchange Board of India ("SEBI")
- (iii) The Guidance Note on Reports in Company Prospectus (Revised 2019) issued by the Institute of Chartered Accountants of India ("ICAI"), as amended from time to time (the "Guidance Note")
- In terms of Schedule-VI of the SEBI (ICDR) Regulations, 2018 and other provisions relating to accounts, We, M/s M S N T & Associates LLP., Chartered Accountants, have been subjected to the peer review process of the Institute of Chartered Accountants of India (ICAI) and hold valid Certificate No. 013922 dated 03 January 2022 issued by the "Peer Review Board" of the ICAI.

ASSOCIATA



- 3. The Company's Board of Directors are responsible for the preparation of the Restated Consolidated Financial Information for the purpose of inclusion in the Offer Document to be filed with Securities and Exchange Board of India, relevant stock exchange and Registrar of Companies, Kanpur in connection with the proposed SME IPO. The Restated Consolidated Financial Information has been extracted by the management from the Audited Financial Statements of the group for the period ended 31st March, 2024, 31st March, 2023 and 31st March 2022, which have been approved by the Board of Directors of the respective companies with in the group. The Board of Directors responsibility includes designing implementing and maintaining adequate internal control relevant to the preparation and presentation of the Restated Consolidated Financial Information. The Board of Directors is also responsible for identifying and ensuring that the Company complies with the Companies Act, (ICDR) Regulations and the Guidance Note.
- 4. We have examined such Restated Consolidated Financial Information taking into consideration:
 - i. The terms of reference to our engagements with the Company letter dated 4th April 2024 requesting us to carry out the assignment, in connection with the Red Herring Prospectus/ Prospectus being issued by the Company for its proposed Initial Public Offering of equity shares in SME Platform of relevant stock Exchange. ("IPO" or "SME IPO").
 - ii. The Guidance Note. The Guidance Note also requires that we comply with the ethical requirements of the Code of Ethics issued by the ICAI.
 - iii. Concepts of test checks and materiality to obtain reasonable assurance based on verification of evidence supporting the Information; and Restated Consolidated Financial Information; and
 - iv. The requirements of Section 26 of the Act and the ICDR Regulations

Our work was performed solely to assist you in meeting your responsibilities in relation to your compliance with the Act, the ICDR Regulations and the Guidance Note in connection with the IPO. We have audited such consolidated financial information of the company for the limited purpose of complying with the requirement of getting its financial statements audited by an audit firm holding a valid peer review certificate issued by the "Peer Review Board" of the ICAI as required by ICDR Regulations in relation to proposed IPO. We have issued our report dated 12th September 2024 on these consolidated financial information to the Board of Directors who have approved these in their meeting held on 12th September 2024.

- 5. In accordance with the requirements of the Act including the rules made there under, ICDR Regulations, Guidance Note and Engagement Letter, we report that:
 - (i) The "restated statement of consolidated asset and liabilities" of the Company as at March 31, 2024, March 31, 2023, and March 31, 2022 examined by us, as attached to this report read with significant accounting policies has been arrived at after making such adjustments and regroupings to the audited consolidated financial statements of the Company, as in our opinion were appropriate.
 - (ii) The "restated statement of Consolidated profit and loss" of the Company for the year ended on March 31, 2024, March 31, 2023, and March 31, 2022 examined by us, as attached to this report read with significant accounting policies has been arrived at after making such adjustments and regroupings to the audited consolidated financial statements of the Company, as in our opinion were appropriate.



- (iii) The "restated statement of consolidated cash flows" of the Company for the year ended on March 31, 2024, March 31, 2023, and March 31, 2022 examined by us, as attached to this report read with significant accounting policies has been arrived at after making such adjustments and regroupings to the audited consolidated financial statements of the Company, as in our opinion were appropriate.
- 6. Based on our examination, we are of the opinion that the restated consolidated financial statements have been prepared after incorporating:
 - a) Regroupings to the audited consolidated financial statements of the Company, as in our opinion were appropriate
 - b) There are no adjustments for the changes in accounting policies retrospectively in respective financial years to reflect the same accounting treatment as per the changed accounting policy for all reporting periods, if any,
 - c) There are no adjustments for prior period and other material amounts in the respective financial year to which they relate and there are no qualifications which require adjustments and
 - d) There are no extra-ordinary items that need to be disclosed separately in the accounts and gualifications requiring adjustments
 - e) There were no qualifications in the Audit Reports issued by the Statutory Auditors for the financial year ended on 31st March 2024, 2023, and 2022 which would require adjustments in this Restated Financial Statements of the Company.
 - These Profits and Losses have been arrived at after charging all expenses f) including depreciation and after making such adjustments/restatements in respect of regroupings as in our opinion are appropriate and are to be read in accordance with the Significant Accounting Polices and Notes to Accounts as set out in attachment to this report.
- 7. Audit of CHANDAN HEALTHCARE LIMITED for the year ended 31st March 2024 & 31st March 2023 is Conducted by us. whereas audit for the financial year ended 31st March 2022 was conducted by M/s Ashish Mishra & Associates and accordingly reliance has been placed on the financial information examined by them for the said year.
- 8. We have also examined the following other financial information relating to the Company prepared by the Management and as approved by the Board of Directors of the Company and annexed to this report relating to the Company for the year ended 31st March 2024, 31st March 2023 and 31st March 2022 proposed to be included in the Offer Document.
- 9. We conducted the audit of Chandan Pharmacy Ltd, one of the three subsidiaries. However, we did not audit the financial statements of the other two subsidiaries, Chandan Diagnostic Limited and Indira Diagnostic Centre & Blood Bank Limited, whose share of profit has been included in the consolidated financial information. The financial statements of these subsidiaries have been audited by other auditors, and their reports have been provided to us by the Company's management. Our opinion on the consolidated financial statements, as it pertains to the amounts and disclosures related to these components, is based solely on the reports of the other auditors:

Particulars	for the year ended March 31, 2024	for the year ended March 31, 2023	for the year ended March 31, 2022
Number of subsidiaries	3	3	3
Revenue of subsidiaries	7,671.53	6,105.60	4,795.94

(Rs in Lakhs)



- 10. The Restated consolidated Financial Information do not reflect the effects of events that occurred subsequent to the respective dates of the reports on the audited consolidated financial statements mentioned above.
- 11. The preparation and presentation of the consolidated Financial Statements referred to above are based on the Audited consolidated financial statements of the Company and are in accordance with the provisions of the Act and ICDR Regulations. The consolidated Financial Statements and information referred to above is the responsibility of the management of the Company.
- 12. The report should not in any way be construed as a re-issuance or re-dating of any of the previous audit reports issued by any other firm of chartered accountants nor should this report be construed as a new opinion on any of the financial statements referred to therein.
- 13. We have no responsibility to update our report for events and circumstances occurring after the date of the report.
- 14. In our opinion, the above consolidated financial information attached to this report read with the respective significant accounting policies and notes to restated statements as attached are prepared after making adjustments and regrouping as considered appropriate and have been prepared in accordance with the Act, ICDR Regulations, Engagement Letter and Guidance Note.
- 15. Our report is intended solely for use of the Board of Directors for inclusion in the Offer Document in connection with the SME IPO. Our report should not be used, referred to or adjusted for any other purpose except with our consent in writing. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing.

Yours faithfully,

For MSNT & ASSOCIATES LLP Chartered Accountants Firm Registration No.018542C/C400322

Navodit Tyagi

Partner Membership No.-533375 UDIN No: 24533375BKFJMP1629 Place: Noida Date: 12/09/2024



Company name :- Chandan Healthcare Limited CIN :- U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021. (All amounts are in ₹ lakhs, unless otherwise stated)

Restated Consolidated Statement of Assets and Liabilities

Particulars	Note No.	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022
I. EQUITY AND LIABILITIES				
(1) Shareholder's funds				
(a) Share capital	3	2,000.00	2,000.00	2,000.00
(b) Minority interest		284.01	276.13	254.31
(c) Reserves and surplus	5	2,109.07	729.89	393.08
(d) Money received against share warrants	-	-	12.2010	-
(2) Share application money pending allotment	1.1	-	1	
(3) Non-current liabilities				
(a) Long-term borrowings	6	1,217.56	789.04	670.08
(b) Deferred tax liabilities(net)	7	139.36	139.43	108.25
(c) Other long-term liabilities	8	0.45	0.65	0.65
(d) Long term provisions	9	305.75	218.41	215.92
(4) Current liabilities				
(a) Short-term borrowings	10	2.983.71	1.346.46	988.09
(b) Trade payables	11			10 10 10 10 10 10 10 10 10 10 10 10 10 1
(i) Total outstanding dues of micro & small enterprises.		626,71	337.45	144.14
(ii) Total outstanding dues of creditors other then micro & small enterprises.		1,517.35	3,156.74	2,515.54
(c) Other current liabilities	12	1,558.91	768.02	819.21
(d) Short term provisions	13	174.49	51.26	44.47
TOTAL		12,917.37	9,813.48	8,153.74
II. ASSETS				24022
(1) Non- current assets				
(a) Property, plant & equipments & intangible assets	14	4,406.11	2,812.33	2,493.34
(i) Property, plant & equipments		Contraction of the		
(ii) Intangible assets		443.27	443.27	443.27
(iii) Capital work in progress				
(iv) Intangible assets under development				
(b) Non-current investments	15	368.72	453.52	610.91
(c) Deferred tax assets(net)	-	-		-
(d) Long -term loans and advances	16	121.60	393.91	131.99
(e) Other non-current assets	17	362.16	355.11	159.15
(2) Current assets				
(a) Current investments	18		286.17	-
(b) Inventories	19	1,824.37	987.12	656.03
(c) Trade receivables	20	2,656.05	2,368.84	2,869.81
(d) Cash and bank balances	21	524.64	204.46	157.63
(e) Short-term loans and advances	22	2.149.29	1,490.82	621.13
(f) Other current assets	23	61.16	17.93	10.48
TOTAL		12,917.37	9,813.48	8,153.74

Corporate information, significant accounting policies and notes to financial statements.

The notes referred to above form an integral part of the financial statement.

For & on behalf of the board of directors As per our report of even date attached Chandan Healthcare Limited For M/s Wsht & Associates LLP Chartered accountants 3 Firm registration no. :- 018542C/C400322 Director & ASSOCIATES Amar singh Asmita singh Managing director Managing director M 10 M Din. :- 01098055 Din. :- 01096328 Nayodit tyagi 018542C/C400322 * Place :- Lucknow Place :- Lucknow Partner Date :- 12-09-2024 Membership no. :- 533375 Date :- 12-09-2024 UDIN no. :- 24533375BKFJMP1629 ERED ACCO Place :- Noida Chandas Rajeev nain Aealtho Date :- 12-09-2024 CFO & Company secretary 2 Place :-- 12-09-2024 1ar Date :- Lucknow Ucknow Ucknow

1 to 38

Company name :- Chandan Healthcare Limited CIN :- U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021. (All amounts are in ₹ lakhs, unless otherwise stated)

A Chatamanta of Deafit and Loos

Restated Consolidated Statements o	f Profit an	nd Loss		and the second
Particulars	Note No.	Restated consolidated figures for the year ended 31st March, 2024	Restated consolidated figures for the year ended 31st March, 2023	Restated consolidated figures for the year ended 31st March, 2022
I. Revenue from operations	24	17,659.01	13,688.94	11,956.35
II. Other income	25	136.85	13.98	35.23
III. Total revenue(I+II)		17,795.86	13,702.92	11,991.58
IV. Expenses: Cost of material consumed Purchase of stock-in-trade Change in inventories of finished goods,work-in-progress and stock-in-trade. Employee benefits expense. Finance Costs Depreciation and amortisation expense Other expenses Total expenses (IV) V. Profit/(loss) before exceptional & extraordinary items and tax (III-IV) VI. Exceptional items	26 27 28 29 30 14 31	1,112.68 7,236.76 (264.47) 3,537.96 275.19 340.40 3,411.33 15,649.85 2,146.01	1,388.00 5,493.56 (410.16) 2,549.09 241.91 208.95 3,730.45 13,201.80 501.12	967.89 5.332.58 (74.28) 1,872.98 170.62 196.06 3,631.75 12,097.60 (106.02)
VII. Profit/(loss) before extraordinary items and tax (V-VI)	1	2,146.01	501.12	(106.02)
VIII. Extraordinary items		-	-	· .
IX. Profit(loss) before tax (VII- VIII)	-	2,146.01	501.12	(106.02)
X. Tax expense of continuing operation:- Current tax Deferred tax		510.57 . (0.07)		3.23
Tax expense(X)		510.50	142.49	3.23
XI. Profit(loss) for the period from continuing operations(after tax) (IX-X)		1,635.51	358.63	(109.25)
XII. Profit/(loss) from discontinuing operations XIII. Tax expense of discontinuing operations		:		
XIV. Profit/(loss) from discontinuing operations (after tax) (XII-XIII)				-
XV. Share of profit/ (loss) transferred to minority interest		7.88	21.82	1.65
XVI. Profit/ (Loss) after tax attributable to owners of the company (XI+XIV-XV)		1,627.63	336.81	(110.90)
XVII. Earnings per equity share: (1) Basic (2) Diluted	32	8.14 8.14	1.68 1.68	(0.55) (0.55)

Corporate information, significant accounting policies and notes to financial statements. The notes referred to above form an integral part of the financial statement

As per our report of even date attached M/s Msnt & Associates LLP For

d accountants dha stration no. :- 018542C/C400322 FÌ m

Navodir tyagi Partner

Membership no. :- 533375 UDIN no. :- 24533375BKFJMP1629 Place :- Noida Date :- 12-09-2024

SSOCIA 018542C/C400323 × CHARA TERED ACCOUNT

For & on behalf of the board of directors although the second sec Chandan Healthcare Limited

Amar singh Managing director Din. :- 01096328 Place :- Lucknow Date ; 12-09-2024

1 to 38 10

all Ar Asmita singh Director Managing director Din. :- 01098055 Place :- Lucknow Date :- 12-09-2024 00

Rajeev nain Rajeev NCFO & Company secretary CFO & ComPlace = 12-09-2024 Secretar Date :- Lucknow

Lealthc

4cknov

S nan

4cknow

Heath

0 C,han

Company name :- Chandan Healthcare Limited CIN :- U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021. (All amounts are in ₹ lakhs, unless otherwise stated)

Restated Consolidated Cash Flow Statement

Particulars	Restated consolidated figures for the year ended 31st March, 2024	Restated consolidated figures for the year ended 31st March, 2023	Restated consolidated figures for the year ended 31st March, 2022
A. Cash flow arising from operating activities			
Profit / (Loss) before tax	2,146.01	501.12	(106.02)
Adjustments related to non-cash & non operating transactions:			
Non cash transactions		249 5 4 19	
Depreciation & amortisation of fixed assets	340.40	208.95	196.06
Bad Debts & Excess written off	3.52	3.88	520.78
Preliminary expenses written off	- 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1	10000000-000	-
Re-measurement (gains) / loss on defined benefit plans	89.77	102.87	85.36
Provision for doubtful debts	5.24		-
Provision for obsolete inventories	6.26	Cole (Notesta	-
Loss(gain) on account of foreign exchange flauctuations			
Other non-cash transactions(specify nature)	-	1.	-
Non operating transactions			
Interest on borrowing	260.72	231.32	160.94
Loss/(profit) on the sale of property, plant & equipments & intangible assets		-	-
Loss/(profit) on the sale of investments	-		
Interest income	(24.50)	(7.75)	(5.86
Dividend income	(75.98)	-	(7.16
Other non-operating transactions(specify nature)	and the second second second	-	
Operating profit/(loss) before working capital changes	2,751.44	1,040.39	844.09
Adjustment for change in working capital:			Start Start
(Increase) / Decrease in inventories	(843.51)	(331.09)	
(Increase) / Decrease in trade receivables	(295.96)	497.10	(1,037.44
(Increase) / Decrease in other current assets	(436.43)	(1,335.02)	(317.59
(Decrease) / Increase in trade paybles	(1,350.13)	834.52	747.45
(Decrease) / Increase in other current liabilities	911.49	(144.80)	430.30
Net cash (used in) / generated from operating activities	736.90	561.10	621.79
Income taxes refund / (paid), net	(490.59)	(111.32)	(11.81)
Net cash flow from operating activities(A)	246.31	449.78	609.98
B. Cash flow arising from investing activities			
Sale/(Purchase) of tangible and intangible assets	(1,954.19)	(527.94)	(664.19
Sale/(Purchase) of non current & current investments	370.97	(128.77)	(423.55
Interest income	24.50	7.75	5.86
Dividend income	75.98		7.16
Other income	-	-	-
Net cash flow from investing activities(B)	(1,482.73)	(648.96)	(1,074.72
C. Cash Flow Arising From Financing Activities		1 1 1 1 1	
Proceeds from issuance of share capital	-	C. M. C.	474.00
Proceeds from/(Payment of) long term & short term borrowings	2,065.77	477.33	149.69
Finance cost paid (including processing fees)	(260.72)	(231.32)	(160.94
Dividend paid	(248.45)		(115.00
Net cash flow from financing activities(C)	1,556.60	246.01	347.75
Net increase/decrease in cash or cash equivalents(A+B+C)	320.18	46.83	(116.99
Cash and cash equivalents at the beginning of the period	204.46	157.63	274.62
Cash and cash equivalents at the end of the period	524.64	204.46	157.63

Corporate information, significant accounting policies and notes to financial statements.

The notes referred to above form an integral part of the financial statement. As periodr report of even date attached Fol M/s Ment & Associates LLP Chartered accountants

Navodit tyagi

Partner Membership no. :- 533375 UDIN no. :- 24533375BKFJMP1629 Place :- Noida Date :- 12-09-2024



1 to 38

Amar singh

HealPate - 12-09-2024

Rajeev nain

BL

Ucknow

Managing director

Din. :- 01096328

Place :- Lucknow

-

CFO & Company secretary Place :- 12-09-2024 Date :- Lucknow

For & on behalf of the board of directors

Chandan Healthcare Limited



ealthc a Ucknow

Jealth

Imit

lea

*

Notes to restated consolidated financial statements.

Note No. :- 1 : Corporate information

Chandan Healthcare Limited, established on September 3, 2003, specializes in operating state-of-the-art laboratories that offer comprehensive pathological investigations. Our services encompass biochemistry, hematology, histopathology, microbiology, and immunology. Additionally, we provide an extensive array of radiology services, including CT scans, X-rays, and MRIs. Committed to accuracy and reliability, Chandan Healthcare supports healthcare professionals and patients by delivering essential diagnostic services.

Notes to restated consolidated financial statements.

Note No. :- 2 : Summary of Significant accounting policies

a) Basis of Preparation of Financial Statements

The financial statements have been prepared in accordance with the historical cost convention, accrual basis, and going concern assumption, as mandated by generally accepted accounting principles (GAAP) in India. GAAP encompasses the mandatory accounting standards specified under Section 133 of the Companies Act, 2013, in conjunction with Rule 7 of the Companies (Accounts) Rules, 2014, and the relevant provisions of the Act (to the extent notified).

Accounting policies have been applied consistently throughout, except where the initial adoption of a new accounting standard or a revision to an existing accounting standard necessitates a change in the previously applied accounting policy.

The financial statements are prepared in accordance with Schedule III of the Companies Act, 2013, which significantly influences their disclosure and presentation. Comparative figures for the previous year have been regrouped or reclassified, as necessary, to align with the current year's classification and disclosure requirements.

b) Use of Estimates

The preparation and presentation of financial statements necessitate the use of estimates and assumptions that impact the reported amounts of assets, liabilities, and contingent liabilities as of the financial statement date, as well as the reported revenues and expenses for the reporting period. Any variances between actual results and estimates are recognized in the period in which they become known or materialize.

Accounting estimates are subject to periodic revisions, and actual results may differ from these estimates. Adjustments to estimates are made when management becomes aware of changes in the circumstances affecting the estimates. Such changes are reflected in the financial statements for the period in which they occur, and their impact is disclosed in the notes to the financial statements if deemed material.

c) Functional and presentation currency

These consolidated financial statements are presented in Indian Rupees (Rs.), which is also the Company's functional currency. All amounts have been rounded to the nearest lakhs, unless otherwise indicated.

d) Current and non-current classification:

The Company classifies an asset as current when:

- it expects to realise the asset, or intends to sell or consume it, in its normal operating cycle;
- it expects to realise the asset within twelve months after the reporting period;
- it holds the asset primarily for the purpose of traiding; or

- the asset is cash or cash equivalent unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non current.

A liability is classified as a current when

- it is expected to be settled in the Company's normal operating cycle;
- the liability is due to be settled within twelve months from the reporting period;
- it is held primarily for the purposes of being trading;

- it does not hold an unconditionl right to defer settlement of the liability for at least twelve months after the reporting period. Terms of a liability that could, at the option of the counter party, result in its settlement by the issue of equity instruments do not affect its classification.

All other liabilities are classified as non-current.

The operating cycle is the time between the acquisition of assets for processing and realisation in cash or cash equivalents. The Company's normal operating cycle is twelve months.

e) Significant accounting policies

i.) Revenue recognition

Revenue from the **sale of goods** is recognized when ownership, along with all significant risks and rewards, has been transferred to the buyer, and when there is no significant uncertainty regarding the amount of consideration to be received from the sale.

Revenue from the **sale of services** is recognized using the **completed service contract method**, provided there is no significant uncertainty regarding the amount of consideration to be received for rendering the service.

Sales are accounted for net of amounts recovered towards gst and sales returns.

Sales returns are recorded upon the actual receipt of returned goods or the settlement of claims.

Revenue arising from the use by others of enterprise resources yielding interest and dividends should only be recognised when no significant uncertainty as to measurability or collectability exists. These revenues are recognised on the following bases:

Interest: On a time proportion basis taking into account the amount outstanding and the rate applicable.

Dividends: When the owner's right to receive payment is established.

ii.) Inventories

Inventories comprise of diagnostic kits ,reagents, laboratory chemicals and consumables, these are measured at lower of cost and net realisable value. The cost of inventories is based on the **first in first out (FIFO) cost formula** and includes expenditure incurred in acquiring the inventories and other costs incurred in bringing them to their present location and condition. Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs necessary to make the sale. The comparison of cost and net realisable value is made on an item-by-ltem basis.

iii.) Property, plant & equipments

The cost of an item of property, plant and equipment shall be recognised as an asset if, and only if it is probable that future economic benefit associated with the item will flow to the Company and the cost of the item can be measured reliably. Items of property, plant and equipment (including capital-work-in progress) are measured at cost, which includes capitalised borrowing costs, less accumulated depreciation and any accumulated impairment losses. Freehold land is carried at historical cost less any accumulated impairment losses.

Cost of an item of property, plant and equipment comprises its purchase price, including non refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the items to its working conditions for its intended use and estimated costs of dismantaling and removing the item and restoring the site on which it is located.

The cost of a self-constructed item of property, plant and equipment comprises the cost of materials and direct labour, any other costs directly attributable to bringing the item to working condition for its intended use, and estimated costs of dismantling and removing the item and restoring the site on which it is located.

Any gain or loss on disposal of an item of property, plant and equipment is recognised in profit or loss.

An item of property, plant and equipmnet is derecognised upon disposal or when no future economic benefits are expecteed to arise from the continued use of asset.

Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Company and the cost of the item can be measured reliably.

iv.) Intangible assets

Intangible assets that are acquired, are recognized at cost initially and carried at cost less accumulated amortization and accumulated impairment loss, if any. Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates.

v.) Depreciation & Amortisation

Depreciation is recognised so as to write off the cost of assets (other than freehold land) less their residual values over their useful lives.

The Company has charged depreciation on property, plant & equipment (PPE) based on the Straight linen Method(SLM) as per useful life specified in schedule II of the Companies Act, 2013.

Amortisation is calculated to write off the cost of intangible assets over their estimated useful lives using the straight line method (SLM) and is included in depreciation and amortisation expense in statement of profit and loss.

Depreciation and amortisation on additions and deletions are restricted to the period of use.

Residual value is considered to be 5% on all the tangible assets.

Assets costing below Rs. 5,000 are depreciated using depreciation rate at 100%.

Depreciation and amortisation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

vi.) Employee benefits

Short-term employee benefits

Short term employee benefits are measured on an undiscounted basis and expensed as the related service is provided. A short term liability is recognised if the Company has a present legal or constructive obligation to pay the amount as a result of past service provided by the employee and the obligation can be estimated reliably.

Defined contribution plans

A defined contribution plan is a post-employment benefit plan where the company's legal or constructive obligation is limited to the amount that it contributes to a seperate legal entity. The company makes specified monthly contributions towards government administered provident fund scheme and employees' state insurance ('ESI') scheme. The company makes specified monthly contributions towards government administered provident fund scheme and employees' state insurance ('ESI') scheme and employees' state insurance ('ESI') scheme. Obligations for contributions to defined contribution plans are expensed as an employee benefits expense in statement of profit and loss in the period in which the related services are rendered by employees.

Defined benefit plans

A defined benefit plan is a post-employment benefit plan other than a defined contribution plan. The company has a defined benefit plan namely gratuity for all its employees. Liability for defined benefit plan is provided on the basis of valuations, as at the balance sheet date, carried out by an independent actuary. The actuarial valuation method used by independent actuary for measuring the liability is the Projected Unit Credit Method. Actuarial gains and losses due to changes in actuarial assumptions and are recognised immediately in the profit and loss account as income or expense. Current and non current liabilities are recognised on the basis of actuarial report.

vii.) Lease

Lease contracts entered by the company majorly pertains for buildings taken on operationg lease to conduct its business in the ordinary course.Leases where the lessor effectively retains substantially all the risks and benefits of the leased assets are classified as operating leases. Operating lease payments are recognized in the statement of profit and loss on a straight line basis over the lease term.Lease agreements are renewable for further period or periods on terms and condition as mutually agreed with the lessor.Variation or escalations clauses in lease rentals are made as per mutually agreed terms and conditions with the lessor.

viii.) Impairment of assets

An asset is treated as impaired when the carrying cost of assets exceeds its recoverable value. An impairment loss is charged to the statement of profit and loss in the year in which an asset is identified as impaired. The impairment loss recognised in prior accounting period is increased/ reversed where there has been change in the estimate of recoverable value. The recoverable value is the higher of the assets' net selling price and value in use. At each reporting date, the Company reviews the carrying amount of assets, to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

ix.) Investments

Current Investments are carried at lower of cost and market value computed Investment wise. Long Term Investments are stated at cost or fair value . Provision for diminution in the value of long term investments is made only if such a decline is other than temporary in the opinion of the management.

x.) Income-tax

Provision for income tax is made on the basis of taxable income for the year at current rates. Tax expense comprises of current tax and deferred tax at the applicable enacted or substantively enacted rates. Current tax represents the amount of income tax payable/ recoverable in respect of the taxable income/ loss for the reporting period. Deferred tax represents the effect of timing difference between taxable income and accounting income for the reporting period that originate in one period and are capable of reversal in one or more subsequent periods.

The deferred tax asset is recognised and carried forward only to the extent that there is a reasonable certainty that the assets will be realised in future. However, where there is unabsorbed depreciation or carried forward loss under taxation laws, deferred tax assets are recognised only if there is virtual certainty of realisation of assets.

Minimum Alternate Tax (MAT) paid in a year is charged to the statement of profit and Loss as current tax. The company recognizes the MAT credit available as an asset only to the extent that there is convincing evidence that the company will pay the normal income tax during the specified period i.e., period for which MAT credit is allowed to be carried forward.

xi.) Provision, contingent liabilities and contingent assets

A **provision** is recognised when the company has a present obligation (legal or constructive) as a result of past event and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on Management's estimate for the amount required to settle the obligation at the balance sheet date.

Contingent liability is a possible obligation arising from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity or a present obligation that arises from past events but is not recognized because it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation or the amount of the obligation cannot be measured with sufficient reliability. The Company does not recognize a contingent liability but discloses its existence in the financial statements.

Contingent assets are neither recognised nor disclosed in the financial statements, since this may result in the recognition of income that may never be realised. However, when the realisation of income is virtually certain, then the related asset is not a contingent asset and is recognized.

Provisions, contingent liabilities and contingent assets are reviewed at each balance sheet date.

xii.) Earnings per share Basic Earnings per share

Basic Earnings Per Share ('EPS') is calculated by dividing the profit attributable to the equity shareholders of the company by the weighted average number of equity shares outstanding during the year.

Diluted Earnings per share

Diluted earnings per share is computed by dividing the profit (considered in determination of basic earnings per share) after considering the effect associated with dilutive potential equity shares by the weighted average number of equity shares considered for deriving basic earnings per share adjusted for the weighted average number of equity shares that would have been issued upon conversion of all dilutive potential equity shares.

xiii.) Cash flow statement

Cash flows are reported using the indirect method, whereby profit for the year is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows are segregated into operating, investing and financing activites. The Company considers all highly liquid investments that are readily convertible to known amounts of cash to be cash equivalents.

xiv.) Cash and cash equivalents

Cash and cash equivalents in the balance sheet and cash flow statement consists of cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities less than three months which are readily convertible to known amounts of cash and which are subject to insignificant risk of changes in value.

xv.) Dividend

The company recognises a liability for any dividend declared but not distributed at the end of the reporting period, when the distribution is authorised and the distribution is no longer at the discretion of the company on or before the end of the reporting period.

xvi.) Related parties transactions

The company has a policy to recognize and identify related party transactions; disclosures of related party transactions have been made wherever applicable.

xvii.) Foreign Currency Transactions

Foreign exchange transactions are recorded at the rates prevailing on the date of transactions. Exchange rate differences arising on foreign exchange transactions settled during the year are recognized in the statement of profit and loss for the year. Monetary assets and liabilities denominated in foreign currencies as at the balance sheet date are translated at the closing exchange rates on that date and the resultant exchange differences are recognized in the statement of profit and loss.Non-monetary items which are carried in terms of historicalcost denominated in a foreign currency should be reported using the exchange rate at the date of the transaction. Non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency should be reported using the exchange rate at the date of the transaction.

xviii.) Borrowing Costs

Borrowing costs that are attributable to acquisition, construction or production of qualifying assets are capitalised as part of such assets. A qualifying asset is an asset that necessarily takes a substantial period of time to get ready for its intended use. All other borrowing costs are recognised as an expense in the period in which they are incurred.

xix.) Events after reporting date

Where events occurring after the balance sheet date provide evidence of conditions that existed at the end of the reporting period, the impact of such events is adjusted within the financial statements. Otherwise, events after the balance sheet date of material size or nature are only disclosed.

Notes to restated consolidated financial statements.

Note No. :- 3 : Share capital

a. Information on authorised, issued, subscribed and paid-up shares

	Restated consolidated	Restated consolidated	Restated consolidated
Particulars	figures as at the		
	end of 31st	end of 31st	end of 31st
	March, 2024	March, 2023	March, 2022
Authorised			
Equity shares with voting rights	2,400.00	2,400.00	2,000.00
(Current year : 24000000 equity shares of Rs.10/- each)			
(Previous year : 24000000 equity shares of Rs.10/- each)			
Total	2,400.00	2,400.00	2,000.00
Issued			
Equity shares with voting rights	2,000.00	2,000.00	2,000.00
(Current year : 20000000 equity shares of Rs.10/- each)			
(Previous year : 20000000 equity shares of Rs.10/- each)			
Total	2,000.00	2,000.00	2,000.00
Subscribed and fully paid			
Equity shares with voting rights	2,000.00	2,000.00	2,000.00
(Current year : 20000000 equity shares of Rs.10/- each)			
(Previous year : 20000000 equity shares of Rs.10/- each)			
Total	2,000.00	2,000.00	2,000.00

Notes to restated consolidated financial statements.

a. The reconciliation of shares.

Particulars	Restated consolidated figures as at the end of 31st March, 2024			Restated consoli	dated figures as a March, 2023	t the end of 31st	Restated consolidated figures as at the end of 31st March, 2022		
r aluculais	No of shares	Paid up value per share	Amount	No of shares	Paid up value per share	Amount	No of shares	Paid up value per share	Amount
Equity shares with voting rights, subscribed and fully paid									
Shares outstanding at the beginning of the year	200.00	10.00	2,000.00	200.00	10.00	2,000.00	200.00	10.00	2,000.00
Add: Fresh shares issued during the year	-	-	-	-	-	-	-	-	-
Add: Bonus shares issued during the year	-	-	-	-	-	-	-	-	-
Less: Shares forfeited/bought back during the year	-	-	-	-	-	-	-	-	-
Shares outstanding at the end of the year	200.00	10.00	2,000.00	200.00	10.00	2,000.00	200.00	10.00	2,000.00

b. Rights, preferences and restrictions of different classes of shares including restrictions on the distribution of dividends and the repayment of capital

Equity shares with voting rights,subscribed and fully paid	
As to dividend:	The shareholders are entitled to receive dividend in proportion to the amount paid up on the equity shares held by
	them.
As to repayment of capital:	In the event of liquidation of the company, the holders of equity shares will be entitled to receive any of the
	remaining assets of the company after distribution of all preferential amounts. The distribution will be in proportion of
	the number of shares held by the shareholders.
As to voting:	The company has only one class of shares referred to as equity shares having a par value of Rs. 10/ Each holder
	of the equity share is entitled to one vote per share.

Notes to restated consolidated financial statements.

c. Details of shareholders holding more than 5% shares of the Company

	Restated consolidated figures as at the end of 31st March, 2024		Restated consolidated figures as at the end of 31st March, 2023			Restated consolidated figures as at the end of 31st March, 2022			
Name of shareholder	No of shares	Paid up value per share	Percentage (%)	No of shares	Paid up value per share	Percentage (%)	No of shares	Paid up value per share	Percentage (%)
Equity shares with voting rights, subscribed and fully paid									
Name of shareholder									
- Amar Anita Holdings (India) Private Limited	58.43	10	29.22%	58.43	10	29.22%	58.43	10	29.22%
- Amar Singh	23.20	10	11.60%	21.20	10	10.60%	21.20	10	10.60%
- Vinay Lamba	15.85	10	7.92%	15.85	10	7.92%	15.85	10	7.92%
- Other shareholders*	102.52	10	51.26%	104.52	10	52.26%	104.52	10	52.26%
Total	200.00		100%	200.00		100%	200.00		100%

*Other shareholders, each holding less than 5% of the total shares, are included here to ensure reconciliation of the total share count with the notes provided above.

d. Disclosure of shareholding of promoters: As at 31st March, 2024

Name of promoter	No of shares as at the beginning of year	Addition	Deletion	No of shares as at the end of year	% of total shares	% Change during the year
Equity shares with voting rights, subscribed and fully paid						
Name of promoter*						
-Alok Singh	3.00	-	-	3.00	1.50%	-
-Amar Singh	21.20	2.00	-	23.20	11.60%	9.43%
-AmarAnita Holdings (India) Pvt Ltd	58.43	-	-	58.43	29.22%	-
-Asmita Singh	1.62	-	-	1.62	0.81%	-
-Shaleen Solanki	9.00	-	-	9.00	4.50%	-
-Vijay Singh	8.99	-	-	8.99	4.50%	-
-Vinay Lamba	15.85	-	-	15.85	7.92%	-

As at 31st March, 2023

Name of promoter	No of shares as at the beginning of year	Addition	Deletion	No of shares as at the end of year	% of total shares	% Change during the year
Equity shares with voting rights,subscribed and fully paid						
Name of promoter*						
-Aasti Singh	0.70	-	-	0.70	0.35%	-
-Amaranita Holdings(I)Pvt.Ltd.	58.43	-	-	58.43	29.22%	-
-Amar Singh	21.20	-	-	21.20	10.60%	-
-Amit Srivastava	3.41	-	-	3.41	1.71%	-
-Anant Singh	1.05	-	-	1.05	0.53%	-
-Asmita Singh	1.62	-	-	1.62	0.81%	-
-Brahm Prakash	0.40	-	-	0.40	0.20%	-
-Deepak Kumar Sirohi	1.80	-	-	1.80	0.90%	-
-Jagjeet Singh Kalsi	2.85	-	-	2.85	1.43%	-
-Rajeev Lochan	2.33	-	-	2.33	1.17%	-
-Rajeev Nain	0.27	-	-	0.27	0.14%	-
-Rajesh Srivastava	0.52	-	-	0.52	0.26%	-
-Rajive Kumar	2.27	-	-	2.27	1.13%	-
-R B Kalia	1.55	-	-	1.55	0.78%	-
-Sandeep Kumar Saraswat	3.08	-	-	3.08	1.54%	-
-Shaleen Solanki	9.00	-	-	9.00	4.50%	-
-Shweta Lamba	4.19	-	-	4.19	2.10%	-
-Subodh Kaul	0.80	-	-	0.80	0.40%	-
-Vijay Singh	8.99	-	-	8.99	4.50%	-
-Vikalp Dixit	3.00	-	-	3.00	1.50%	-
-Vikas Lamba	5.00	-	-	5.00	2.50%	-
-Vinay Lamba	15.85	-	-	15.85	7.92%	-
-Vishal Lamba	1.54	-	-	1.54	0.77%	-

As at 31st March, 2022

Name of promoter	No of shares as at the beginning of year	Addition	Deletion	No of shares as at the end of year	% of total shares	% Change during the year
Equity shares with voting rights,subscribed and fully paid						
Name of promoter*						
- Amar Singh	21.20	-	-	21.20	10.60%	-
- AmarAnita Holdings (India) Private Limited	58.43	-	-	58.43	29.22%	-
- Amit Srivastava	3.41	-	-	3.41	1.71%	-
- Asmita Singh	1.62	-	-	1.62	0.81%	-
- Deepak Kumar Sirohi	1.80	-	-	1.80	0.90%	-
- Dharmendra Singh Malik	2.42	-	-	2.42	1.21%	-
- G B Singh	2.18	-	-	2.18	1.09%	-
- Jagjeet Singh Kalsi	2.85	-	-	2.85	1.43%	-
- Rajeev Lochan	2.33	-	-	2.33	1.17%	-
- Rajive Kumar	2.27	-	-	2.27	1.13%	-
- Sandeep Kumar Saraswat	3.08	-	-	3.08	1.54%	-
- Shweta Lamba	4.19	-	-	4.19	2.10%	-
- Vijay Singh	8.99	-	-	8.99	4.50%	-
- Vikalp Dixit	3.00	-	-	3.00	1.50%	-
- Vikas Lamba	5.00	-	-	5.00	2.50%	-
- Vinay Lamba	15.85	-	-	15.85	7.92%	-
- Virender Singh	2.47	-	-	2.47	1.24%	-
- Vishal Lamba	1.54	-	-	1.54	0.77%	-

*Individuals designated or to be designated by the company as promoters in its annual return.

Notes to restated consolidated financial statements.

Note No. :- 4 : Minority Interest

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022
Opening Balance	276.13	254.31	252.66
Share of profit/ (loss) transferred to minority interest	7.88	21.82	1.65
Total	284.01	276.13	254.31

a. Disclosure of Subsidiaries' Share in Consolidated Net Assets and Profit and Loss

Particulars		olidated figures 31st March, 2024		olidated figures 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022		
	Net Assets	Profit & Loss	Net Assets	Profit & Loss	Net Assets	Profit & Loss	
Parent Company							
Chandan Healthcare Limited	4,109.07	1,627.63	2,729.89	336.81	2,393.08	(110.90)	
Total Consolidated Net Assets & Net Profit	4,109.07	1,627.63	2,729.89	336.81	2,393.08	(110.90)	
Parent Indian Subsidaries							
Chandan Diagnostic Limited	47.42	1.67	49.09	(0.53)	48.56	1.23	
Chandan Pharmacy Limited	530.17	15.79	514.37	47.36	482.01	2.69	
Indira Diagnostic Centre & Blood Bank Limited	(140.48)	16.40	(156.87)	(92.37)	(64.50)	20.30	
Total Subsidaries Net Assets & Net Profit	437.11	33.86	406.59	-45.54	466.07	24.22	
Percentage of Subsidaries share in consolidated net assets and							
profit							
Chandan Diagnostic Limited (% Holding 67.99%)	1.15%	0.10%	1.80%	-0.16%	2.03%	-1.11%	
Chandan Pharmacy Limited (% Holding 53.56%)	12.90%	0.97%	18.84%	14.06%	20.14%	-2.43%	
Indira Diagnostic Centre & Blood Bank Limited (% Holding 100%)	-3.42%	1.01%	-5.75%	-27.42%	-2.70%	-18.30%	
Tottal percentage	10.64%	2.08%	14.89%	-13.52%	19.48%	-21.84%	

b. Disclosure of minority Interest in all subsidiaries

Particulars		olidated figures a 31st March, 2024			olidated figures a 31st March, 2023		Restated consolidated figures as at the end of 31st March, 2022		
Particulars	Share Capital	Reserve & Surplus	Total	Share Capital	Reserve & Surplus	Total	Share Capital	Reserve & Surplus	Total
Parent Indian Subsidaries									
Chandan Diagnostic Limited	31.01	(15.18)	15.83	31.01	(15.71)	15.30	31.01	(15.54)	15.47
Chandan Pharmacy Limited	15.00	253.18	268.18	15.00	245.84	260.83	15.00	223.85	238.84
Indira Diagnostic Centre & Blood Bank Limited	-	-	-	-	-	-	-	-	-
Total	46.01	238.00	284.01	46.01	230.13	276.13	46.01	208.31	254.31

Notes to restated consolidated financial statements.

	Note No	:- 5 : Re	eserves and	surplus
--	---------	-----------	-------------	---------

Particulars	Restated consolidated figures as at the end of 31st	Restated consolidated figures as at the end of 31st	Restated consolidated figures as at the end of 31st
	March, 2024	March, 2023	March, 2022
Surplus/Retained earning			
Opening balance	729.89	393.08	839.07
Less :- Dividend on equity shares	(248.45)	-	(115.00)
Less: Minority Interest in reserve & surplus	-	-	(206.66)
Less: Parent Share In pre acquisition reserve & surplus	-	-	(13.43)
Securities premium account	-	-	-
Add :- Profit/(Loss) for the period	1,627.63	336.81	(110.90)
Closing balance	2,109.07	729.89	393.08

Notes to restated consolidated financial statements.

Note No. :- 6 : Long-term borrowings

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March. 2022
Secured			
Term loans - From banks - From other parties Unsecured Term loans - From banks	1,217.56 -	789.04	434.58 234.61
- From other parties	-	-	- 0.89
Total	1,217.56	789.04	670.08

a. Reconciliation of current and non current portion of long term liabilities

Particulars		ted consolidated figures as at the end of 31st March, 2024			nsolidated fig 31st March	ures as at the end of , 2023	Restated consolidated figures as at the end of 31st March, 2022		
	Non current	Current	Total	Non current Current Total				Current	Total
Secured									
Term loans									
- From banks LTBS	1,217.56	585.60	1,803.16	789.04	249.75	1,038.79	434.58	234.13	668.71
- From other parties LTBS	-	-	-	-	-	-	234.61	126.40	361.01
Unsecured									
Term loans									
- From banks LTBUS	-	-	-	-	-	-	-	-	-
- From other parties LTBUS	-	-	-	-	-	-	0.89	0.48	1.37
Total	1,217.56	585.60	1,803.16	789.04	249.75	1,038.79	670.08	361.01	1,031.09

Notes to restated consolidated financial statements.

b. Other disclosure on term loan

b. Other disclosure on term loan Particulars	Restated co figures as a 31st Mar		figures as a	onsolidated at the end of rch, 2023	Restated consolidated figures as at the end of 31st March, 2022		Details of repayment terms and maturity*		Details of repayment terms and mat		Nature of Security
	Amount	ROI	Amount	ROI	Amount	ROI	Particulars	Terms			
Secured Term Loan from Bank State Bank of India [41626319793]	35.42	7.95%	69.62	7.95%	-	-	Amount of installments due No. of installment due# Sanction date Principal amount Repayment amount EMI amount	42.63 15.00 28/02/2023 83.00 85.26 2.84			
State Bank of India [41626315993]	208.67	7.95%	279.12	7.95%	-	-	Loan period (Month)# Last Instalment date Amount of installments due No. of installment due# Sanction date Principal amount Repayment amount EMI amount Loan period (Month)#	05/06/2025 259.73 36.00 28-02-2023 308.00 360.73 7.21 50.00	Collateral Security: A pari passu charge on immovable property, shared equally with other lenders who have similar security interests in the		
State Bank of India [41626340656]	16.63	7.95%	33.39	7.95%	-	-	Last Instalment date Amount of installments due No. of installment due# Sanction date Principal amount Repayment amount EMI amount Loan period (Month)# Last Instalment date	40.44 25.00 28-02-2023 40.00 43.67 1.62 27.00	same property. This provides additional security for the lender, aligning their claim with those of other creditors. 3. Personal Guarantee: A guarantee provided by all directors of the borrowing entity, holding them personally liable for the loan obligations in the event of default by the borrowing entity. 4. Corporate Guarantee: A guarantee provided by AmarAnita Holdings (India) Pvt Ltd, ensuring		
State Bank of India [41623614536]	42.48	8.30%	45.67	7.95%	-	-	Amount of installments due Amount of installments due No. of installment due# Sanction date Principal amount Repayment amount EMI amount Loan period (Month)# Last Instalment date	55.85 47.00 28-02-2023 46.00 5.823 1.19 49.00 01-02-2027	that it will fulfill the loan obligations if the primary borrower fails to do so.		
Indusind Bank [73200008552]	160.45	8.75%	270.51	8.30%	-	-	Amount of installments due No. of installment due# Sanction date Principal amount Repayment amount EMI amount Loan period (Month)# Last Instalment date	311.48 29.00 01-07-2022 340.24 386.66 10.74 36.00 07-08-2025			
Yes Bank Limited [MEN00180126]	68.90	9.00%	85.93	8.75%	-	-	Amount of installments due No. of installment due# Sanction date Principal amount Repayment amount EMI amount Loan period (Month)# Last Instalment date	105.74 53.00 21-07-2022 96.66 119.71 2.00 60.00 22-07-2027	The loan is secured by a first pari passu charge on the assets acquired using the proceeds of this loan, establishing a primary security interest.		
Yes Bank Limited [MEN001801285372]	14.74	7.95%	18.26	9.00%	-	-	Amount of installments due No. of installment due# Sanction date Principal amount Repayment amount EMI amount Loan period (Month)# Last Instalment date	22.64 54.00 09-08-2022 20.20 25.16 0.42 60.00 22-08-2027			

Punjab National Bank [241400CH00000028]	1,255.88	7.95%	236.30	7.95%	-	-	Amount of installments due	2,400.72	The loan is secured by:
							No. of installment due#	61.00	1. A first pari passu charge on the assets
							Sanction date	31-03-2023	acquired with the proceeds of the loan.
							Principal amount	1,255.88	2 The personal guarantee of all directors of the
							Repayment amount	1,889.09	borrowing entity.
							EMI amount Loan period (Month)#	39.36	3. The corporate guarantee of AmarAnita
							Last Instalment date		Holdings (India) Pvt Ltd.
Indian Overseas Bank [068403510000002]	_	-	-	-	114.18	7.85%		51-03-2020	
Indian Overseas Bank [068403510000018]	-	-	-	-	46.85	9.15%			
Indian Overseas Bank [068403602000002]	-	-	-	-	349.27	9.15%			
Indian Overseas Bank [068403602000003]	-	-	-	-	50.00	9.15%			
Indian Overseas Bank [068403707000002]	-	-	-	-	108.42	9.15%			
Term loans from other parties							Not Applicable	Not Applicable	Not Applicable
Moneywie Financial Services P Ltd [ME00023]	-	-	-	-	84.87	14.00%			
Moneywie Financial Services P Ltd [ME00013]	-	-	-	-	221.99	12.50%			
Moneywise Financial Services Pvt Ltd [CHL01]	-	-	-	-	54.13	12.50%			
Unsecured									
Term loans from other parties					1.38	15.00%			
Capital Float Financial Services Private Ltd	-	-	-	-	1.30	15.00%			
Less:- Current maturities of all long-term borrowings	(585.60)	-	(249.75)	-	(361.01)				
	、 · · · · · ,		、 ,		, ,				
Total	1,217.56		789.04		670.08				

* These are with respect to the balance sheet date.

The figures are presented in absolute terms and are not expressed in lakhs.

Notes to restated consolidated financial statements.

Note No. :- 7 : Deferred tax liabilities(Net)

Particulars		—	Restated consolidated figures as at the end of 31st March, 2022
Deferred tax liabilities(Net)	139.36	139.43	108.25
Total	139.36	139.43	108.25

a. Disclosures regarding the components of net deferred tax liabilities

Particulars	-	•	Restated consolidated figures as at the end of 31st March, 2022
Provision for gratuity	(79.97)	(25.89)	-
Provision for doubtful debts	(1.32)	-	-
Provision for obsolete inventories	(1.58)	-	-
W.D.V of property, plant & equipments & intangible assets	222.22	165.32	108.25
Total	139.36	139.43	108.25

Notes to restated consolidated financial statements.

Note No. :- 8 : Other long -term liabilities

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022
Other long-term liabilities - Trade deposits and security deposits which are not in the nature of borrowings	0.45	0.65	0.65
Total	0.45	0.65	0.65

Notes to restated consolidated financial statements.

Note No. :- 9 : Long term provisions

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022
Provision for gratuity	305.75	218.41	215.92
Total	305.75	218.41	215.92

a. Details of employee benefits as required by the accounting standard 15 (revised) employee benefits are as under:

The company has classified the various benefits provided to employee's as under:-

I. Defined contribution plans

- a. Employee's provident fund.
- b. Employee's state insurance.

During the year, the company has recognised the following amounts in the profit and loss account:

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022
Employers' contribution to provident fund*	75.92	36.23	33.96
Employers' contribution to employee's state insurance*	30.91	14.50	13.99
Total	106.83	50.73	47.95

* Included in Contribution to Provident and Other Funds (Refer Note No. 28 Employee benefits expense)

II. Defined benefit plans

Gratuity disclosures as per accounting standard-15

(i) Table Showing Changes in Present Value of Obligations

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022
Present value of the obligation at the beginning of the period	235.93	250.74	190.15
Interest cost	17.69	18.18	13.79
Current service cost	52.37	31.80	32.97
Past Service Cost	-	-	-
Benefits paid (if any)	(7.96)	(117.68)	(24.77)
Actuarial (gain)/loss	19.71	52.89	38.60
Present value of the obligation at the end of the period	317.73	235.93	250.74
(ii) Key results (The amount to be recognized in the Balance Sheet):			
Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022

Present value of the obligation at the end of the period	317.73	235.93	250.74
Fair value of plan assets at end of period	-	-	-
Net liability/(asset) recognized in Balance Sheet and related analysis	317.73	235.93	250.74
Funded Status - Surplus/ (Deficit)	(317.73)	(235.93)	(250.74)

(iii) Expense recognized in the statement of Profit and Loss:

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022	
Interest cost	17.69	18.18	13.79	
Current service cost	52.37	31.80	32.97	
Past Service Cost	-	-	-	
Expected return on plan asset	-	-	-	
Net actuarial (gain)/loss recognized in the period	19.71	52.89	38.60	
Expenses to be recognized in P&L #	89.77	102.87	85.36	

Included in Provision for gratuity (Refer Note No. 28 Employee benefits expense)

(iv) Current & Non Current Liability :

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022
Current Liability (Short Term)^	34.68	30.37	34.82
Non Current Liability (Long Term)	305.75	218.41	215.92
Total Liability	340.43	248.78	250.74

^ Included in Provision for gratuity (Refer Note No. 12 Short term provisions)

(v) Reconciliation of liability in balance sheet

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022
Opening gross defined benefit liability/ (asset)	235.93	250.74	190.15
Expenses to be recognized in P&L	89.77	102.87	85.36
Benefits paid (if any)	(7.96)	(117.68)	(24.77)
Closing gross defined benefit liability/ (asset)	317.73	235.93	250.74

(vi) Actuarial assumptions provided by the company and employed for the calculations are tabulated:

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022
Discount rate	7.25 % p.a.	7.50 % p.a.	7.50 % p.a.
Salary Growth Rate	8.00 % p.a.	8.00 % p.a.	8.00 % p.a.
Mortality	IALM 2012-14	IALM 2012-14	IALM 2012-14
Expected rate of return	-	-	-
Attrition / Withdrawal Rate (per Annum)	5.00% p.a.	5.00% p.a.	5.00% p.a.

Notes to restated consolidated financial statements.

Note No. :- 10 : Short-term borrowings

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022
Secured			
Loans repayable on demand			
- From banks-Overdraft(OD)	114.18	-	405.93
- From banks-Cash credid(CC)	1,673.77	970.19	101.55
- From other parties	-	-	-
Loans and advances from related parties	610.16	126.52	119.60
Current maturities of all long-term borrowings			
- From banks	585.60	249.75	234.13
- From other parties	-	-	126.40
For current maturities of all long-term borrowings refer Note 5a & 5b. Unsecured			
Current maturities of all long-term borrowings			
- From banks	-	-	-
- From other parties	-	-	0.48
For current maturities of all long-term borrowings refer Note 5a & 5b.			
Total	2,983.71	1,346.46	988.09

a. Other dislosures

	Restated cons	Restated consolidated figures Restated cor					
	as at the end	the end of 31st March, as at the end of 31st Ma			st March, figures as at the end of		
Particulars	20	24		23		March. 2022	
Fatticulais		Nature of		Nature of		Nature of	
	Amount	security and	Amount	security and	Amount	security and	
		other terms		other terms		other terms	
Secured							
Loans repayable on demand							
- From banks-Overdraft(OD)							
		Sanctioned				Sanctioned	
- Icici Bank Limited		against FDs with				against FDs with	
	114.18	ICIC Bank	-		73.65	ICIC Bank	
						Hypothecation of	
- Indian Overseas Bank						stock and book	
	-	-	-	-	332.28	debt	
- From banks-Cash credid(CC)							
		Hypothecation of		Hypothecation of		Hypothecation of	
		stock and book		stock and book		stock and book	
- State Bank of India (CC)	1,673.77	debt	970.19	debt	101.55	debt	
		Unsecure		Unsecure		Unsecure	
		loan,repayable		loan,repayable		loan,repayable on	
Loans and advances from related parties		on demand,		on demand,		demand, From	
		From Diectors		From Diectors		Diectors and	
	-	and relative.	126.52	and relative.	119.60	relative.	

Notes to restated consolidated financial statements.

Note No. :- 11 : Trade payables

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022	
Trade payables - Total outstanding dues of micro enterprises and small enterprises - Total outstanding dues of other then micro enterprises	626.71	337.45	144.14	
and small enterprises	1,517.35	3,156.74	2,515.54	
Total	2,144.06	3,494.19	2,659.68	

a. Trade payables ageing schedule

As at 31st March, 2024

			Outstanding for following periods from due date of payment			date of payment			
Particulars	Unbilled dues	Not dues	Less than 1	1-2	2-3	More than	TOTAL		
			year	years	years	3 years			
Not Disputed									
MSME	-	626.71	-	-	-	-	626.71		
Others	-	-	1,517.35	-	-	-	1,517.35		
Disputed									
MSME	-	-	-	-	-	-	-		
Others	-	-	-	-	-	-	-		
Total	-	626.71	1,517.35	-	-	-	2,144.06		

As at 31st March, 2023

			Outstanding for following periods from due date of payment				
Particulars	Unbilled dues	Not dues	Less than 1	1-2	2-3	More than	TOTAL
			year	years	years	3 years	
Not Disputed							
MSME	-	337.45	-	-	-	-	337.45
Others	-	-	3,156.74	-	-	-	3,156.74
Disputed							
MSME	-	-	-	-	-	-	-
Others	-	-	-	-	-	-	-
Total	-	337.45	3,156.74	-	-	-	3,494.19

As at 31st March, 2022

			Outstanding	e of payment			
Particulars	Unbilled dues	Not dues	Less than 1	1-2	2-3	More than	TOTAL
			year	years	years	3 years	
Not Disputed							
MSME	-	144.14	-	-	-	-	144.14
Others	-	-	2,515.54	-	-	-	2,515.54
Disputed							
MSME	-	-	-	-	-	-	-
Others	-	-	-		-	-	-
Total	-	144.14	2,515.54	-	-	-	2,659.68

b. Disclosure as per MSMED Act, 2006

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022
Payble			
Principle overdue as per MSMED Act,2006.	-	-	-
Principle not due as per MSMED Act,2006.	626.71	337.45	144.14
Interest payble under section 16 of MSMED Act, 2006 - On principle paid beyond due date as per MSMED			
Act,2006 - On principle payble beyond due date as per MSMED	-	-	-
Act,2006	-	-	-
- Carried forward from the last year	-	-	-
Other interest	-	-	-
Total	626.71	337.45	144.14
Paid			
Principle paid beyond the due date as per MSMED			
Act,2006	-		-
Interest paid under section 16 of MSMED Act, 2006	-	-	-
Total	-	-	-

Notes to restated consolidated financial statements.

Note No. :- 12 : Other current liabilities

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022
Advances from customers	1,070.22	344.62	542.68
TDS payble	59.77	43.20	58.95
GST payble	10.97	3.21	6.03
Salary, Bonus, Gratuity, Reimbursements etc. payble to staff	387.19	370.47	192.18
Contribution towards PF payble	15.04	5.18	14.03
Contribution towards ESI payble	2.99	1.34	5.34
Total	1,558.91	768.02	819.21

Notes to restated consolidated financial statements.

Note No. :- 13 : Short term provisions

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022	
Provision for employee benefits Provision for gratuity Others	34.68	30.37	34.82	
Provision for taxation	139.81	20.89	9.65	
Total	174.49	51.26	44.47	

Notes to restated consolidated financial statements.

Note No. :- 14 : Property, plant & equipments & intangible assets

Consolidated as at 31st March, 2024

		Gross b	lock		Accu	mulated depre	ciation	Net block			
Description	Figures as at the beginining of 1st April, 2023	Additions during the year	Disposal s during the year	Restated consolidated figures as at the end of 31st March, 2024	Figures as at the beginining of 1st April, 2023	For the year	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023		
Tangible Assets											
Property, plant and equipment											
Computers	368.92	115.54	-	484.46	295.70	39.71	335.41	149.05	73.22		
Electric Installation	94.78	15.71	-	110.49	77.38	2.76	80.14	30.35	17.40		
Office Interior & Rennovation	398.12	146.03	14.97	529.18	293.24	18.78	312.02	217.16	104.88		
Buildings	310.13	12.38	-	322.51	80.61	4.93	85.54	236.97	229.52		
Plant and equipment	4,393.07	1,575.89	4.72	5,964.24	2,211.73	247.32	2,459.05	3,505.19	2,181.34		
Furniture and fixtures	143.04	16.13	-	159.17	102.43	6.67	109.10	50.07	40.61		
Vehicles	88.45	16.58	0.32	104.71	76.01	3.34	79.35	25.37	12.45		
Office equipment	253.47	55.93	-	309.40	100.56	16.89	117.45	191.95	152.91		
Total	6,049.97	1,954.19	20.01	7,984.15	3,237.64	340.40	3,578.04	4,406.11	2,812.33		
Intangible Assets											
Goodwill	443.27	-	-	443.27	-	-	-	443.27	443.27		
Total	443.27	-	-	443.27	-	-	-	443.27	443.27		

Consolidated as at 31st March, 2023

		Gross b	lock		Accui	mulated depre	ciation	Net block		
Description	Figures as at the beginining of 2022	Additions during the year	Disposal s during the year	Figures as at the end of 31st March, 2023	Figures as at the beginining of 2022	For the year	Figures as at the end of 31st March, 2023	Figures as at the end of 31st March, 2023	Figures as at the end of 31st March, 2022	
Tangible Assets										
Property, plant and equipment										
Computers	340.34	33.58	5.00	368.92	271.49	24.20	295.70	73.22	68.85	
Electric Installation	90.53	4.25	-	94.78	75.77	1.61	77.38	17.40	14.76	
Office Interior & Rennovation	366.45	31.66	-	398.12	290.43	2.80	293.24	104.88	76.02	
Buildings	310.13	-	-	310.13	76.73	3.87	80.61	229.52	233.39	
Plant and equipment	3,990.30	402.76	-	4,393.07	2,050.99	160.74	2,211.73	2,181.34	1,939.31	
Furniture and fixtures	121.18	21.86	-	143.04	98.96	3.47	102.43	40.61	22.22	
Vehicles	80.03	8.42	-	88.45	74.83	1.18	76.01	12.45	5.20	
Office equipment	223.07	30.40	-	253.47	89.48	11.08	100.56	152.91	133.58	
Total	5,522.03	532.94	5.00	6,049.97	3,028.69	208.95	3,237.64	2,812.33	2,493.34	
Intangible Assets										
Goodwill	443.27	-	-	443.27	-	-	-	443.27	443.27	
Total	443.27	-	-	443.27		-	-	443.27	443.27	

Consolidated as at 31st March, 2022

		Gross block			Accu	mulated depre	ciation	Net block		
Description	Figures as at the beginining of 2021	Additions during the year	Disposal s during the year	Figures as at the end of 31st March, 2022	Figures as at the beginining of 2021	For the year	Figures as at the end of 31st March, 2022	Figures as at the end of 31st March, 2022	Figures as at the end of 31st March, 2021	
Tangible Assets										
Property, plant and equipment										
Computers	280.41	59.93	-	340.34	259.12	12.37	271.49	68.85	21.28	
Electric Installation	81.48	9.05	-	90.53	73.69	2.07	75.77	14.76	7.79	
Office Interior & Rennovation	300.27	66.19	-	366.45	283.10	7.33	290.43	76.02	17.17	
Buildings	310.13	-	-	310.13	72.80	3.94	76.73	233.39	237.33	
Plant and equipment	3,491.22	499.09	-	3,990.30	1,897.95	153.04	2,050.99	1,939.31	1,593.27	
Furniture and fixtures	112.88	8.29	-	121.18	96.59	2.37	98.96	22.22	16.30	
Vehicles	73.20	6.83	-	80.03	72.70	2.13	74.83	5.20	0.50	
Office equipment	208.25	14.81	-	223.07	76.68	12.81	89.48	133.58	131.58	
Total	4,857.84	664.19	-	5,522.03	2,832.63	196.06	3,028.69	2,493.34	2,025.21	
Intangible Assets										
Goodwill	-	443.27	-	443.27	-	-	-	443.27	-	
Total	-	443.27	-	443.27	-	-	-	443.27	-	

Notes to restated consolidated financial statements.

Note No. :- 15 : Non-current investments

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022
Investments in equity instruments	368.72	453.52	610.91
Total	368.72	453.52	610.91

a.Disclosure on investment in equity instrument

As at 31st March, 2024

Name of body corporate	Nature of Investment	Paid up value/share	Fully or partly paid	(%) holding	No of shares	lssue price	Amount	Basis of Valuation	Quoted/ Unquoted Investment
Chandan Institute of Medical Science Limited	Associates	10	Fully paid	17.58%	1.25	270	337.72	Valuers Va	Unquoted
Chandan Diagnostic Limited	Subsidiaries	10	Fully paid	99.99%	3.10	10	31.00	Cost	Unquoted
Total							368.72		

As at 31st March, 2023

Name of body corporate	Nature of Investment	Paid up value/share	Fully or partly paid	(%) holding	No of shares	lssue price	Amount	Basis of Valuation	Quoted/ Unquoted Investment
Chandan Institute of Medical Science Limited	Associates	10	Fully paid	17.58%	123.01	2.75	337.74	Cost	Unquoted
Chandan Diagnostic Limited	Subsidiaries	10	Fully paid	99.99%	3.10	10.00	31.00	Cost	Unquoted
Chandan Hospital Limited	Associates	10	Fully paid	1.60%	8.48	10.00	84.79	Cost	Unquoted
Total							453.52		

As at 31st March, 2022

Name of body corporate	Nature of Investment	Paid up value/share	Fully or partly paid	(%) holding	No of shares	lssue price	Amount	Basis of Valuation	Quoted/ Unquoted Investment
Chandan Hospital Limited	Minority Interest	2.5	Partly paid	1.46%	37.10	6.53	242.20	Cost	Unquoted
Chandan Institute of Medical Sciences Limited	Associates	10	Partly paid	17.58%	123.01	2.75	337.72	Cost	Unquoted
Chandan Diagnostic Limited	Subsidiaries	10	Fully paid	99.99%	3.10	10.00	31.00	Cost	Unquoted
Total							610.91		

Notes to restated consolidated financial statements.

Note No. :- 16 : Long -term loans and advances

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022
Secured, considered good			
Capital advances	44.06	316.37	38.74
Loans and advances to related parties	-	-	-
Unsecured, considered good			
Income tax refund due	77.54	77.54	93.25
Total	121.60	393.91	131.99

Chandan Healthcare Limited U85110UP2003PLC193493 www.chandan.co.in (All amounts are in ₹ lakhs, unless otherwise stated)

Notes to restated consolidated financial statements.

Note No. :- 17 : Other non-current assets

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022
Secured, considered good Security Deposits Banks deposits with more than twelve months maturity	97.38 264.78	59.61 295.50	54.98 104.17
Total	362.16	355.11	159.15

Notes to restated consolidated financial statements.

Note No. :- 18 : Current investments

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022	
Investments in equity instruments	-	286.17	-	
Total	-	286.17	-	

a.Disclosure on investment in equity instrument

As at 31st March, 2023

Name of body corporate	Nature of Investment	Paid up value/share	Fully or partly paid	(%) holding	No of shares	Issue price	Amount	Basis of Valuation	Quoted/Unquot ed Investment
Chandan Hospital Limited,	Associates	10	Fully paid	9.66%	28.62	10	286.17	Cost	Unquoted
Total							286.17		

Note No. :- 19 : Inventories

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022
Stock-in-trade	1,251.59	987.12	656.03
Stores,spares and consumables (Refer # below)	579.04	-	-
Less: Provision for stock obsolescence	(6.26)	-	-
Total	1,824.37	987.12	656.03

The company has revised its accounting policy regarding the treatment of consumables transferred to various diagnostic centers. Under the previous policy, these consumables were expensed at the time of transfer. Given the significance of the consumable stock consistently held at these centers, the company has adopted a new policy wherein consumables transferred to diagnostic centers are recognized as inventory at those centers and are expensed only when consumed or used.

As a result of this policy change, the profit before tax for the current financial year has increased by Rs 579.04 Lakhs, representing a 27.70% increase. This adjustment reflects a one-time impact on the current year's profit and is not expected to materially affect profitability in future periods.

In accordance with Accounting Standard (AS) 5, "*Net Profit or Loss for the Period, Prior Period Items and Changes in Accounting Policies*," prior period items include errors discovered in the preparation of financial statements for one or more prior periods. Such errors may arise from mathematical mistakes, incorrect application of accounting policies, misinterpretation of facts, or oversight. Given that the revised policy addresses an error in the application of the previous accounting policy, the resulting increase in profit of Rs 579.04 Lakhs should be classified as a prior period item.

Chandan Healthcare Limited U85110UP2003PLC193493 finance@chandan.co.in website: otherwise stated)

Notes to restated consolidated financial statements.

Note No. :- 20 : Trade receivables

Particulars	Restated consolidated figures as at the end of 31st March, 2024	-	Restated consolidated figures as at the end of 31st March, 2022
Secured, considered good			
Trade receivables	2,661.29	2,368.84	2,869.81
Unsecured, considered good			
Trade receivables Doubtful	-	-	-
Trade receivables	-	-	-
Less: Provision for bad and doubtful trade receivables	(5.24)	-	-
Total	2,656.05	2,368.84	2,869.81

a. Trade receivable ageing schedule As at 31st March, 2024

			Out	Outstanding for following periods from due date of receipt				
Particulars	Unbilled dues	Not dues	Less than 6 Month	6 Months - 1 year	1-2 years	2-3 years	More than 3 years	TOTAL
UnDisputed								
Trade Receivables – considered good	-	555.68	2,105.61	-	-	-	-	2,661.29
Trade Receivables – considered doubtful	-	-	5.24	-	-	-	-	5.24
Disputed								
Trade Receivables – considered good	-	-	-	-	-	-	-	-
Trade Receivables – considered doubtful	-	-	-	-	-	-	-	-
Total	-	555.68	2,110.85	-	-	-	-	2,656.05

As at 31st March, 2023

			Outstanding for following periods from due date of receipt					
Particulars	Unbilled dues	Not dues	Less than 6 Month	6 Months - 1 year	1-2 years	2-3 years	More than 3 years	TOTAL
UnDisputed								
Trade Receivables – considered good	-	346.41	2,022.43	-	-	-	-	2,368.84
Trade Receivables – considered doubtful Disputed	-	-	-	-	-	-	-	
Trade Receivables – considered good	-	-	-	-	-	-	-	-
Trade Receivables – considered doubtful	-	-	-	-	-	-	-	-
Total	-	346.41	2,022.43	-	-	-	-	2,368.84

As at 31st March, 2022

			Outstanding for following periods from due date of receipt					
Particulars	Unbilled dues	Not dues	Less than 6 Month	6 Months - 1 year	1-2 years	2-3 years	More than 3 years	TOTAL
UnDisputed								
Trade Receivables – considered good	-	223.35	2,646.46	-	-	-	-	2,869.81
Trade Receivables – considered doubtful Disputed	-	-	-	-	-	-	-	-
Trade Receivables – considered good	-	-	-	-	-	-	-	-
Trade Receivables – considered doubtful	-	-	-	-	-	-	-	-
Total	-	223.35	2,646.46	-	-	-	-	2,869.81

Chandan Healthcare Limited U85110UP2003PLC193493 www.chandan.co.in (All amounts are in ₹ lakhs, unless otherwise stated)

Notes to restated consolidated financial statements.

Note No. :- 21 : Cash and bank balances

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022	
Cash and cash equivalents				
Balances with banks	355.33	71.82	46.42	
Cash on hand	34.65	107.58	84.12	
Others				
Bank deposits with more than three months maturity	134.66	25.06	27.09	
Total	524.64	204.46	157.63	

Notes to restated consolidated financial statements.

Note No. :- 22 : Short-term loans and advances

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022
Secured, considered good			
Advance to supplier	280.28	219.71	19.98
Advance to employees	219.12	84.63	79.34
Loans and advances to related parties	1,649.66	1,137.87	513.76
Unsecured, considered good			
Income tax refund due	0.23	48.61	8.05
Total	2,149.29	1,490.82	621.13

a. Other dislosures

		Restated consolidated figures as at the end of 31st March, 2024		idated figures as 1st March, 2023	s Restated consolidated figures as at the end of 31st March, 2022		
Particulars		Nature of security and		Nature of security and		Nature of security and	
		other terms		other terms		other terms	
Loans and advances to related parties		Unsecure Ioan,repayable		Unsecure Ioan,repayable		Unsecure Ioan,repayable	
	1,649.66	on demand.	1,137.87	on demand.	513.76	on demand.	
Total	1,649.66		1,137.87		513.76		

Notes to restated consolidated financial statements.

Note No. :- 23 : Other current assets

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022
Secured			
Input tax credit(ITC)-GST	9.14	13.18	10.48
Security Deposits	-	4.75	-
Prepaid expenses	14.52	-	-
Other	37.50	-	-
Total	61.16	17.93	10.48

Notes to restated consolidated financial statements.

Note No. :- 24 : Revenue from operations

Particulars	Restated consolidated figures for the year ended 31st March, 2024	Restated consolidated figures for the year ended 31st March, 2023	Restated consolidated figures for the year ended 31st March, 2022
Sale of products	7,908.32	,	
Sale of services	9,749.18	7,545.43	6,149.19
Other operating revenues			
Sale of scrap	1.51	0.41	-
Less: Excise duty	-	-	-
Total	17,659.01	13,688.94	11,956.35

Notes to restated consolidated financial statements.

Note No. :- 25 : Other income

Particulars	Restated consolidated figures for the year ended 31st March, 2024	Restated consolidated figures for the year ended 31st March, 2023	Restated consolidated figures for the year ended 31st March, 2022
On current investments			
Interest on fixed deposits	24.50	7.75	5.86
Dividends from other companies	75.98	-	7.16
Other			
Other Interest Income	5.93	0.29	1.53
Other non-operating income	30.44	5.94	20.68
Total	136.85	13.98	35.23

Notes to restated consolidated financial statements.

Note No. :- 26 : Cost of material consumed

Particulars	Restated consolidated figures for the year ended 31st March, 2024	Restated consolidated figures for the year ended 31st March, 2023	Restated consolidated figures for the year ended 31st March, 2022
Stores,spares and consumables	1,112.68	1,388.00	967.89
Total	1,112.68	1,388.00	967.89

Consumption disclosed in Note is on the basis of derived figures rather then actual records of issue.

Notes to restated consolidated financial statements.

Note No. :- 27 : Purchase of stock-in-trade

Particulars	Restated consolidated figures for the year ended 31st March, 2024	Restated consolidated figures for the year ended 31st March, 2023	Restated consolidated figures for the year ended 31st March, 2022
Purchase of stores,spares and consumables	7,236.76	5,493.56	5,332.58
Total	7,236.76	5,493.56	5,332.58

Notes to restated consolidated financial statements.

Note No. :- 28 : Change in inventories of finished	goods,work-in-progress and stock-in-trade.

	Particulars	Restated consolidated figures for the year ended 31st March, 2024	Restated consolidated figures for the year ended 31st March, 2023	Restated consolidated figures for the year ended 31st March, 2022
Opening stock:				
Stock-in-trade		987.12	576.96	502.68
		987.12	576.96	502.68
Closing stock:				
Stock-in-trade		1,251.59	987.12	576.96
		1,251.59	987.12	576.96
	Total	(264.47)	(410.16)	(74.28)

Notes to restated consolidated financial statements.

Note No. :- 29 : Employee benefits expense.

Particulars	Restated consolidated figures for the year ended 31st March, 2024	Restated consolidated figures for the year ended 31st March, 2023	Restated consolidated figures for the year ended 31st March, 2022
Salaries and wages	3,331.05	2,186.59	1,724.09
Contribution to provident and other funds	106.83	50.73	47.95
Provision for gratuity	89.77	102.87	85.36
Staff welfare expense	10.31	208.90	15.58
Total	3,537.96	2,549.09	1,872.98

Notes to restated consolidated financial statements.

Note No. :- 30 : Finance costs

Particulars	Restated consolidated figures for the year ended 31st March, 2024	Restated consolidated figures for the year ended 31st March, 2023	Restated consolidated figures for the year ended 31st March, 2022
Interest expense on borrowings	248.07	180.19	159.87
Other borrowing costs			
Loan processing charges	12.65	51.13	1.07
Bank charges	14.47	10.59	9.68
Total	275.19	241.91	170.62

Note No. :- 31 : Other expenses

Particulars	Restated consolidated figures for the year ended 31st March, 2024	Restated consolidated figures for the year ended 31st March, 2023	Restated consolidated figures for the year ended 31st March, 2022
Repair & maintence- Plant & equipments	75.60	133.26	73.60
Repair & maintenance-Building	33.62	34.21	21.29
Repair & maintence- Other	58.42	28.29	20.00
Baddebts & Writtenoff	14.66	3.88	520.78
Payment to auditors	10.66	1.13	1.22
Rent	447.75	360.81	303.57
Electricity expenses	174.90	130.96	107.56
Fuel expenses	41.18	51.38	41.81
Travelling and conveyance	771.05	1,117.97	1,015.77
Legal and professional fees (professional fees to doctor consultants and others) & other related expenditures	1,034.99	1,073.53	947.78
Books, periodicals & certifications	0.61	2.55	2.11
Commission expenses	0.17	569.22	270.96
Advertisement, publicity, marketing & business promotion expenses	114.23	31.69	22.13
Provision for doubtful debts	5.24	-	-
Provision for obsolete inventories	6.26	-	-
Communication expenses(Telephone & internet expenses)	37.83	22.31	21.97
Insurance	6.70	5.56	3.55
Postage & courier charges	3.35	10.34	10.05
Rates and taxes	0.54	22.81	82.21
Outsourced testing expenses	364.56	55.85	79.54
CSR Expenses	6.06	-	-
Discount to customers	2.43	-	-
Other miscellaneous expenses	200.52	74.70	85.85
Total	3,411.33	3,730.45	3,631.75

a. Payment to the auditor

Particulars	cor figu year	Restated nsolidated ires for the ended 31st arch, 2024	Restated consolidated figures for the year ended 31st March, 2023	Restated consolidated figures for the year ended 31st March, 2022
For statutory audit		7.73	0.93	0.94
For tax audit		1.50	0.20	0.28
Out of Pocket Audit Expenses		1.14	-	-
Stock Audit Fees		0.30	-	-
Total		10.66	1.13	1.22

b. Prior period items

Particulars	Restated consolidated figures for the year ended 31st March, 2024	Restated consolidated figures for the year ended 31st March, 2023	Restated consolidated figures for the year ended 31st March, 2022
Rent	11.66	-	-
Electricity expenses	11.00	-	-
Communication expenses(Telephone & internet expenses)	0.36	-	-
Rates and taxes	1.87	-	-
Other miscellaneous expenses	0.48	-	-
Total	25.37	-	-

c. Disclosure of expenditure in foreign currency during the financial year.

Particulars	Restated consolidated figures for the year ended 31st March, 2024	Restated consolidated figures for the year ended 31st March, 2023	Restated consolidated figures for the year ended 31st March, 2022
Royalty	-	-	-
Legal, professional and consultancy charges	-	-	-
Interest	-	-	-
Other matters(Specify nature)	-	0.44	-
Total	-	0.44	-

Notes to restated consolidated financial statements.

Note No. :- 32 : Earning per share

Basic/Diluted earnings per share are calculated by dividing the Net profit or Loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.

Particulars	Restated consolidated figures for the year ended 31st March, 2024	Restated consolidated figures for the year ended 31st March, 2023	Restated consolidated figures for the year ended 31st March, 2022
Numerator Earning available to equity share holders(EAESH) Denominator Weighted average outstanding equity share capital	1,627.63 200	336.81 200	(110.90) 200
Earnings Per Rupees of Equity Share Capital (Basic/ Diluted)	8.14	1.68	(0.55)

Note No. :- 33 : Disclosure regarding Transactions with Related Parties in terms of Accounting Standard - 18

Name of the related party	Nature of the relationship 31st March 2024	Nature of the relationship 31st	Nature of the relationship 31st
		March 2023	March 2022
A. Enterprises that directly or indirectly control/controlled by/under	r		
common control with, the reporting enterprise			
Chandan Diagnostic Limited- PAN: AABCC9315J #	Common director	Holding 67.99% of share capital	
Chandan Diagnostic Linited- PAN. AABCC93133 #	Common director		Holding 67.99% of share capital
Chandan Hospital Limited - PAN: AABCC9314K #	Common director	Holding 9.66% of share capital	
			Holding 9.66% of share capital
Indira Diagnostic Centre & Blood Bank Limited - PAN: AABCI0214L #	Common director	Holding 100% of share capital	Holding 100% of share capital
Chandan Pharmacy Limited - PAN: AAHCC1459M #	Common director	Holding 53.56% of share capital	
			Holding 53.56% of share capital
Chandan Institute Of Medical Sciences Limited - PAN: AAJCC1470E	Holding 17.58% of share capital	Holding 17.58% of share capital	
			Holding 17.58% of share capital
Cendana Pharmaceuticlas Private Limited - PAN: AAKCC1991P	Common director	Common director	Common director
Amaranita Holdings (I) Private Limited - PAN: AAHCA1540R	Common director	Common director	Common director
Chandan Singh Foundation - PAN: AAATC2479F	Common director and trustee	Common director and trustee	Common director and trustee
B. Associates and joint ventures of the reporting enterprise includir	a		
invesing party and venturer of said associates and joint ventures	5		
Dr Amar Singh - PAN: AGQPS5396H - DIN: 01096328	Managing director of company (MD)	Managing director of company	Managing director of company
0		(MD)	(MD)
Asmita Singh - PAN: AWSPS3853M - DIN: 01098055	Director of company	Director of company	Director of company
Virendra Singh - PAN: AFSPS0571B - DIN: 01099343	Director of company*	Relative of director	Relative of director
Vinay Lamba - PAN: AAXPL5673R - DIN: 01220153	Director of company	Relative of director	Relative of director
Vijay Singh - PAN: AILPS1503P - DIN: 02778087	Director of company	Director of company	Director of company
Aasti Singh - PAN: FRPPS0695A - DIN: 06973933	Director of company	Director of company	Director of company
Anant Singh - PAN: AWSPS3852L - DIN: 00969364	Director of company	Director of company	Director of company
Rishi Bhushan Kalia - PAN: ALVPK6157A - DIN: 08074018	Director of company	Director of company	Director of company
Hari Shanker Dixit - PAN: AARPD6602Q - DIN: 02383137	Director of company	Director of company	Director of company
Sandeep Kumar saraswat - PAN: APGPS5745F - DIN: 08354660	Director of company	Director of company	Director of company
Rajeev Nain - PAN: AIVPN6380K	Key managerial personnel (CFO & Company secretary)		Key managerial personnel (CFO
		& Company secretary)	& Company secretary)
Mohammad Mohsin Rizvi - PAN: AQXPR3626G	Relative of director	Relative of director	Relative of director
Anita Singh - PAN: ARVPS1208G	Relative of director	Relative of director	Relative of director
Vishal Lamba - PAN: ABUPL4208N	Relative of director	Relative of director	Relative of director
Ajai Singh - PAN: AHNPS7885B	Relative of director	Relative of director	Relative of director
Nisha Lamba - PAN: AATPL6545J	Relative of director	Relative of director	Relative of director
Pragya Singh - PAN: DJVPS5075J	Relative of KMP	Relative of KMP	Relative of KMP
Shaivalini Singh - PAN: CURPS9141R	Relative of director	Relative of director	Relative of director
Vikash Lamba - PAN: ACLPL2389Q	Relative of director	Relative of director	Relative of director

During the financial year, the company divested its investments in certain subsidiaries and associates. As a result of these transactions, these entities are no longer classified as subsidiaries or * During the financial year, the individual ceased to serve as a director

a. Details of transactions with related parties and amounts receivable/(payable) as at the beginning and end of the year:

Name of related party	Nature of Transaction	Restated consolidated figures for the year ended 31st March, 2024	Restated consolidated figures for the year ended 31st March, 2023	Restated consolidated figure for the year ended 31st Mar 2022
asti Singh	Opening Balance Payable(Receivable)	18.00	(0.07)	
	Dividend for the Year Payment	0.70 (48.70)	- (2.00)	(0)
	Receipt	(40.70)	(2.00) 0.07	(0
	Salary	10.00	-	
	Professional fee	20.00	20.00	
- Amer Cinch	Closing Balance Payable(Receivable)	(0.00) 11.52	18.00	(0
r Amar Singh	Opening Balance Payable(Receivable) Dividend for the Year	21.20	0.96	2
	Professional fee	-	0.88	
	Bonus for the Year	14.00	-	
	Salary	310.00	220.00	
	Payment Reimbursement	(339.88) 0.75	(210.32)	(174
	Closing Balance Payable(Receivable)	17.59	11.52	2
nita Singh	Opening Balance Payable(Receivable)	(0.00)	6.86	1
-	Salary	35.26		27
	Reimbursement	-	-	7
	Recipt	-	10.00	8
	Commission Gratuity	-	6.60 20.00	
	Payment	- (35.26)	(43.46)	(37
	Closing Balance Payable(Receivable)	(0.00)	(0.00)	
nant Singh	Opening Balance Payable(Receivable)	(0.00)	0.06	
	Salary	-	-	
	Dividend for the Year	1.05	-	
	Advance Payment	- (1.05)	- (0.06)	3(3)
	Closing Balance Payable(Receivable)	(1.03)	(0.00)	(3
ishi Bhushan Kalia	Opening Balance Payable(Receivable)	-	-	Ì
	Professional fee	43.85	46.10	
	Dividend for the Year	-	-	
	Payment Closing Balance Payable(Receivable)	(43.85) 0.00	(46.10)	(4
ari Shanker Dixit	Opening Balance Payable(Receivable)	-		
	Advance	-	-	
	Dividend for the Year	4.00	-	
	Payment	(4.00)	-	(2
and the Olympic	Closing Balance Payable(Receivable)	-	-	
smita Singh	Opening Balance Payable(Receivable) Dividend for the Year	3.33 1.62	44.49	:
	Deposit	-	0.75	
	Reimbursement	-	4.32	
	Advance	-	-	
	Bonus for the Year	35.00	-	
	Salary	123.50	60.00	(5)
	Payment Closing Balance Payable(Receivable)	(159.48) 3.97	(106.24) 3.33	(5 ⁻ 44
inay Lamba	Opening Balance Payable(Receivable)	1.32	0.69	
	Deposit	-	-	
	Payment	(107.42)	(77.36)	(5)
	Advance	-	-	
	Reimbursement Dividend for the Year	- 15.85	-	10
	Bonus for the Year	10.00	-	· · · · · · · · · · · · · · · · · · ·
	Salary	86.60	78.00	
	Closing Balance Payable(Receivable)	6.35	1.32	
jay Singh	Opening Balance Payable(Receivable)	20.03	4.32	
	Dividend for the Year Deposit	8.99	•	
	Reimburesement	-	-	
	Advance	1.54	0.36	
	Gratuity	-	19.94	
	Payment	(31.67)	(19.58)	
	Salary Closing Balance Payable(Receivable)	3.75 2.64	15.00 20.03	2
ndeep Kumar saraswat	Opening Balance Payable(Receivable)		- 20.03	
	Dividend for the Year	3.08		
	Payment	(3.08)	-	(
	Closing Balance Payable(Receivable)	-	-	
rendra Singh Chaudhry	Opening Balance Payable(Receivable) Dividend for the Year	8.08	0.00	
	Salary	2.47	-	
	Professional fee			
	Gratuity		20.00	
	Payment	(10.54)	(11.93)	
ta sea Marta	Closing Balance Payable(Receivable)	0.00	8.08	
jeev Nain	Opening Balance Payable(Receivable) Dividend for the Year	0.66 0.24	9.69	
	Advance	0.24	-	
	Chandan Hospital LTD	(45.27)	-	
	Gratuity		-	1
	Professinal fee		16.50	(0)
	Payment	(3.78)	(25.53)	
	Salary Closing Balance Payable(Receivable)	49.34 2.22	- 0.66	2
ai Singh	Opening Balance Payable(Receivable)			
g	Dividend for the Year	1.00	-	
	Payment	(1.00)	-	(
	Closing Balance Payable(Receivable)	-	-	
sha Lamba	Opening Balance Payable(Receivable)	(0.88)	-	
	Dividend for the Year	2.23	-	

	Receipt	0.88	- 1	
	Payment	(2.23)	(14.67)	(1.12)
Pragya Singh	Closing Balance Payable(Receivable) Opening Balance Payable(Receivable)		(0.88)	
riagya Singii	Salary	14.19	-	-
	Payment	(14.19)	-	-
Shaivalini Singh	Closing Balance Payable(Receivable) Opening Balance Payable(Receivable)	-	•	
Sharvanni Singn	Dividend for the Year	0.23		0.12
	Payment	(0.23)	-	(0.12)
Vikas Lamba	Closing Balance Payable(Receivable) Opening Balance Payable(Receivable)	- 78.10	- 70.56	- 71.10
	Dividend for the Year	5.00	-	2.50
	Payment	(88.22)	(20.85)	(33.92)
	Advance Salary	-	8.32 12.00	9.48 13.98
	Gratuity	-	8.08	-
	Reimbursement	3.98		7.41
	Receipt Closing Balance Payable(Receivable)	1.23 0.09	78.10	70.56
Vishal Lamba	Opening Balance Payable(Receivable)	11.25	(4.07)	0.21
	Dividend for the Year	1.54	-	0.77
	Advance Loan	-	4.81	0.80 0.80
	Salary	-	9.00	8.67
	Gratuity	11.25	11.25	-
	Payment Reimbursement	(25.04) 1.00	(9.74)	(19.78)
	Closing Balance Payable(Receivable)	(0.00)	- 11.25	(4.07)
Chandan Hospital Limited	Opening Balance Payable(Receivable)	197.86	169.12	173.81
	Opening Balance Investment in equity share capital	(286.17)	(157.40)	(71.55)
	Receipt Dividend Income	2,757.18 (42.93)	272.86	612.53
	Sales	(311.69)	(244.13)	(218.79)
	Share sales	286.17	286.16	-
	Share purchase Payment	- (1,750.84)	(414.93)	(85.85) (398.43)
	Closing Balance Investment in equity share capital	(1,730.04)	(286.17)	(157.40)
	Closing Balance Payable(Receivable)	849.58	197.86	169.12
Chandan Institute of Medical Sciences Limited	Opening Balance Payable(Receivable) Opening Balance Investment in equity share capital	158.83 (222.97)	- (222.97)	(0.01)
	Share sales	(222.57)	(222.97)	- 222.97
	Share Purchase	-	-	(222.97)
	Receipt	-	158.83	-
	Payment Closing Balance Investment in equity share capital	(155.56) (222.97)	(222.97)	(222.95)
	Closing Balance Payable(Receivable)	3.27	158.83	(222.97)
Chandan Pharmacy Limited	Opening Balance Payable(Receivable)	565.96	91.84	32.80
	Opening Balance Investment in equity share capital Sales	(474.00) (16.09)	(474.00) (24.60)	(474.00) (173.69)
	Purchase	20.23	12.18	187.99
	Receipt	-	486.55	127.88
	Dividend Income Share sales	(23.35) 474.00	-	-
	Payment	(543.83)	-	(83.14
	Closing Balance Investment in equity share capital	-	(474.00)	(474.00)
Chandan Singh Foundation	Closing Balance Payable(Receivable) Opening Balance Payable(Receivable)	2.92	565.96	91.84
	CSR	6.06	-	-
	Payment	(6.06)	-	-
	Closing Balance Payable(Receivable) Opening Balance Payable(Receivable)	-	- 19.60	- 77.64
Chandan Diagnostic Limited				
Chandan Diagnostic Limited	Opening Balance Investment in equity share capital	45.98 (65.85)		(65.85
Chandan Diagnostic Limited	Opening Balance Investment in equity share capital Share sales	(65.85) 65.85	(28.85) -	37.00
Chandan Diagnostic Limited	Opening Balance Investment in equity share capital Share sales Payment	(65.85) 65.85 (45.98)	(28.85) - (10.62)	37.00 (58.04
Chandan Diagnostic Limited	Opening Balance Investment in equity share capital Share sales Payment Closing Balance Investment in equity share capital	(65.85) 65.85	(28.85) -	37.00 (58.04)
Chandan Diagnostic Limited Indra Diagnostic Centre & Blood Bank Limited	Opening Balance Investment in equity share capital Share sales Payment Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Payable(Receivable)	(65.85) 65.85 (45.98) - - 348.70	(28.85) - (10.62) (28.85) 8.98 300.33	37.00 (58.04 (28.85) 19.60 245.57
	Opening Balance Investment in equity share capital Share sales Payment Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Investment in equity share capital	(65.85) 65.85 (45.98) -	(28.85) - (10.62) (28.85) <u>8.96</u> 300.33 (491.69)	37.00 (58.04 (28.85 19.60 245.57 (491.69)
	Opening Balance Investment in equity share capital Share sales Payment Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Payable(Receivable) Opening Balance Investment in equity share capital Sales	(65.85) 65.85 (45.98) - - - 348.70 (491.69) -	(28.85) - (10.62) (28.85) 8.98 300.33	37.00 (58.04 (28.85 19.60 245.57 (491.69)
	Opening Balance Investment in equity share capital Share sales Payment Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Investment in equity share capital	(65.85) 65.85 (45.98) - - 348.70	(28.85) - (10.62) (28.85) <u>8.96</u> 300.33 (491.69)	37.00 (58.04 (28.85 19.60 245.57 (491.69 (9.51
	Opening Balance Investment in equity share capital Share sales Payment Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Payable(Receivable) Opening Balance Investment in equity share capital Sales Share sales Receipt Payment	(65.85) 65.85 (45.98) - - - 348.70 (491.69) -	(28.85) (10.62) (28.85) 8.98 300.33 (491.69) (7.51) - 55.88	37.00 (58.04 (28.85 19.60 245.57 (491.69 (9.51
	Opening Balance Investment in equity share capital Share sales Payment Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Payable(Receivable) Opening Balance Investment in equity share capital Sales Share sales Receipt Payment Closing Balance Investment in equity share capital	(65.85) 65.85 (45.98) - - 348.70 (491.69) - 491.69	(28.85) 	37.00 (58.04 (28.85 19.60 245.57 (491.69 (9.51 - 409.45 (345.18 (491.69
Indra Diagnostic Centre & Blood Bank Limited	Opening Balance Investment in equity share capital Share sales Payment Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Payable(Receivable) Opening Balance Investment in equity share capital Sales Share sales Receipt Payment	(65.85) 65.85 (45.98) - - - - - - - - - - - - - - - - - - -	(28.85) (10.62) (28.85) 8.98 300.33 (491.69) (7.51) - 55.88	37.00 (58.04 (28.85 19.60 245.57 (491.69 (9.51 - 409.45 (345.18 (491.69
	Opening Balance Investment in equity share capital Share sales Payment Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Payable(Receivable) Opening Balance Investment in equity share capital Sales Share sales Receipt Payment Closing Balance Investment in equity share capital Cosing Balance Payable(Receivable) Opening Balance Payable(Receivable) Receipt	(65.85) 65.85 (45.98) - - - - 491.69 - - (348.70) - - - - - - - - - - - - - - - - - - -	(28.85) (10.62) (28.85) 8.98 300.33 (491.69) (7.51) - 55.88 (491.69) 348.70 -	37.00 (58.04 (28.85 19.60 245.57 (491.69 (9.51 - 409.45 (345.18 (491.69
Indra Diagnostic Centre & Blood Bank Limited	Opening Balance Investment in equity share capital Share sales Payment Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Payable(Receivable) Opening Balance Investment in equity share capital Sales Share sales Receipt Payment Closing Balance Investment in equity share capital Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Payable(Receivable) Receipt Payment Closing Balance Payable(Receivable) Opening Balance Payable(Receivable)	(65.85) 65.85 (45.98) - - - 491.69 - (348.70) - - (348.70) - - - - 44.68 (44.68)	(28.85) (10.62) (28.85) 8.98 300.33 (491.69) (7.51) 5.88 (491.69) 348.70	37.00 (58.04 (28.85 19.60 245.57 (491.69 (9.51
Indra Diagnostic Centre & Blood Bank Limited	Opening Balance Investment in equity share capital Share sales Payment Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Payable(Receivable) Opening Balance Payable(Receivable) Opening Balance Investment in equity share capital Sales Share sales Receipt Payment Closing Balance Investment in equity share capital Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Payable(Receivable) Payment Payment Purchase Closing Balance Payable(Receivable)	(65.85) 65.85 (45.98) - - - - 491.69 - - (348.70) - - - - - - - - - - - - - - - - - - -	(28.85) 	37.00 (58.04 (28.85 19.60 245.57 (491.69 (9.51 (345.18 (491.69 300.33 - - - - - - - - - - - - - - - - - -
Indra Diagnostic Centre & Blood Bank Limited	Opening Balance Investment in equity share capital Share sales Payment Closing Balance Investment in equity share capital Opening Balance Payable(Receivable) Opening Balance Payable(Receivable) Opening Balance Investment in equity share capital Sales Share sales Receipt Payment Closing Balance Investment in equity share capital Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Payable(Receivable) Opening Balance Payable(Receivable) Closing Balance Payable(Receivable) Opening Balance Payable(Receivable)	(65.85) 65.85 (45.98) - - 348.70 (491.69) - - (348.70) - - (348.70) - - - - - 44.68 (44.68) (44.68) 4.57 4.57	(28.85) (10.62) (28.85) 8.98 300.33 (491.69) (7.51) - - - (491.69) (7.51) - - - - - - - - - - - - -	37.00 (58.04 (28.85 19.60 245.57 (491.69
Indra Diagnostic Centre & Blood Bank Limited	Opening Balance Investment in equity share capital Share sales Payment Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Payable(Receivable) Opening Balance Investment in equity share capital Sales Share sales Receipt Payment Closing Balance Investment in equity share capital Closing Balance Investment in equity share capital Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Payable(Receivable) Closing Balance Payable(Receivable) Opening Balance Payable(Receivable)	(65.85) 65.85 (45.98) - - - - - (491.69) - - (348.70) - - (348.70) - - - - - - - - - - - - -	(28.85) 	37.00 (58.04 (28.85 19.60 245.57 (491.69
Indra Diagnostic Centre & Blood Bank Limited	Opening Balance Investment in equity share capital Share sales Payment Closing Balance Investment in equity share capital Opening Balance Payable(Receivable) Opening Balance Payable(Receivable) Opening Balance Investment in equity share capital Sales Share sales Receipt Payment Closing Balance Investment in equity share capital Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Payable(Receivable) Opening Balance Payable(Receivable) Closing Balance Payable(Receivable) Opening Balance Payable(Receivable)	(65.85) 65.85 (45.98) - - 348.70 (491.69) - - (348.70) - - (348.70) - - - - - 44.68 (44.68) (44.68) 4.57 4.57	(28.85) (10.62) (28.85) 8.98 300.33 (491.69) (7.51) - - - (491.69) (7.51) - - - - - - - - - - - - -	37.00 (58.04 (28.85 19.60 245.57 (491.69
Indra Diagnostic Centre & Blood Bank Limited	Opening Balance Investment in equity share capital Share sales Payment Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Payable(Receivable) Opening Balance Investment in equity share capital Sales Share sales Receipt Payment Closing Balance Investment in equity share capital Closing Balance Investment in equity share capital Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Investment in equity share capital Professional Fee Comission Dividend	(65.85) 65.85 (45.98) - - - - - - (491.69) - - (348.70) - - (348.70) - - - - - - - - - - - - -	(28.85) (10.62) (28.85) 8.98 300.33 (491.69) (7.51) 	37.00 (58.04) (28.85 19.60 245.57 (491.69 (9.51) - - 409.45 (345.18 (491.69 300.33 300.33 - - - (135.60 584.3 29.22 - - 29.22
Indra Diagnostic Centre & Blood Bank Limited	Opening Balance Investment in equity share capital Share sales Payment Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Payable(Receivable) Opening Balance Investment in equity share capital Sales Share sales Receipt Payment Closing Balance Investment in equity share capital Closing Balance Investment in equity share capital Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Payable(Receivable) Receipt Payment Purchase Closing Balance Payable(Receivable) Opening Balance Investment in equity share capital Professional Fee Comission Dividend	(65.85) 65.85 (45.98) - - - 491.69 - (348.70) - - (348.70) - - - - - - - - - - - - - - - - - - -	(28.85) 	37.00 (58.04 (28.85 19.60 244.57 (491.69) (9.51 - - 409.45 (345.18 (491.69) 300.33 - - - - - - - - - - - - - - - - - -
Indra Diagnostic Centre & Blood Bank Limited	Opening Balance Investment in equity share capital Share sales Payment Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Payable(Receivable) Opening Balance Investment in equity share capital Sales Share sales Receipt Payment Closing Balance Investment in equity share capital Closing Balance Investment in equity share capital Closing Balance Investment in equity share capital Closing Balance Payable(Receivable) Opening Balance Investment in equity share capital Professional Fee Comission Dividend	(65.85) 65.85 (45.98) - - - - - - (491.69) - - (348.70) - - (348.70) - - - - - - - - - - - - -	(28.85) (10.62) (28.85) 8.98 300.33 (491.69) (7.51) 	245.57 (491.69) (9.51) 409.45 (345.18) (491.69) 300.33

Note No. :- 33 : Analytical ratios

Particulars	figures as a	Restated consolidated Restated consolidated igures as at the end of 31st March, 2024 31st March, 2023 ended 31st March		figures as at the end of		the year
Current Ratio						
Total current assets	7,215.51	1.05	5,355.34	0.95	4,315.08	0.96
Total current liabilities	6,861.17	1.00	5,659.93	0.00	4,511.45	0.00
Debt-to- Equity Ratio						
Total liabilities	4,201.27	1.02	2,135.50	0.78	1,658.17	0.69
Total shareholder's equity	4,109.07	1.02	2,729.89	0.70	2,393.08	0.00
Debt service coverage ratio						
EBIT	2,406.73	0.74	732.44	0.46	54.92	0.05
Current debt obligation	3,244.43	0.74	1,577.78	0.40	1,149.03	0.00
Return on Equity (%)						
PAT	1,627.63	47.60%	336.81	13,15%	(110.90)	-4.64%
Average shareholder's equity	3,419.48	11.0070	2,561.48	10.1070	2,387.72	1.01%
Inventory turnover ratio (in days)						
365* Average inventory	5,14,239	29.12	2,99,875	21.91	2,31,236	19.34
Sales	17,659		13,689	2	11,956	10101
<u>Trade receivables turnover ratio (in days)</u>						
365* Average account receivables	9,17,999	66.91	9,56,054	92.61	9,53,122.54	87.89
Net credit sales	13,720		10,324		10,844	
<u>Trade payables turnover ratio (in days)</u>						
365* Average trade payble	10,28,981	76.18	11,23,081	114.20	8,04,881	75.16
Net credit purchase	13,506		9,834		10,709	10.10
Net capital turnover ratio						
Sales	17,659	709.91	13,689	(54.65)	11,956	(68.86)
Average working capital	24.87		(250.48)	(0.000)	(173.64)	(00.00)
Net profit ratio (%)						
PAT	1,627.63	9.22%	336.81	2.46%	(110.90)	-0.93%
Sales	17,659.01	0.2270	13,688.94	2.10%	11,956.35	0.00 //
Return on Capital Employed (%)						
EBIT	2,407	35.04%	732	15.51%	55	1.34%
Average (Shareholder's equity + Current & Non current borrowings)	6,867.93	00.0470	4,723.54	10.0170	4,098.20	1.0470

Notes to restated consolidated financial statements.

Note No. :- 34 : Contingent liabilities and commitments

Particulars	Restated consolidated figures for the year ended 31st March, 2024Restated consolidated figures for the year ended 31st March, 2023Figures for the year 31st March, 2023		the year ended figures for the year ended			
	No of cases	Amount	No of cases	Amount	No of	Amount
Claims against the company not acknowledged as debts						
1) District consumer disputes redressal forum	11.00	64.98	11.00	75.18	11.00	75.18
2) State consumer disputes redressal commission	2.00	1.98	2.00	1.98	2.00	1.98
3) Labour court	6.00	28.52	5.00	28.41	5.00	28.41
4) District and session court	9.00	29.52	5.00	10.18	4.00	9.84
Direct tax matters	1.00	137.75	1.00	137.75	1.00	137.75
Guarantees						
Guarantee provided to the State Bank of India in relation to borrowings undertaken by Chandan Hospital Limited.	10.00	1,223.67	5.00	850.67	-	-
Guarantee provided to the State Bank of India in relation to borrowings undertaken by Chandan Pharmacy Limited.	1.00	227.76	1.00	159.37	-	-
Total	40.00	1,714.18	30.00	1,263.54	23.00	253.17

Notes to restated consolidated financial statements.

Note No. :- 36 : Segment reporting

Primary segments - Business Segments

The company primarily operates state-of-the-art laboratories providing comprehensive pathological investigations and radiology services. Other activities conducted by the company are ancillary to its main business and do not significantly impact the financial statements. Consequently, in accordance with Accounting Standard 17 on Segment Reporting, the company has identified a single reportable business segment: "Diagnostics Services." As a result, segment information has not been disclosed.

Secondary segments - Geographical Segments

The company operates primarily in india and there is no other significant geographical segment.

Note No. :- 37 : CSR expenditure

Particulars	Restated consolidated figures for the year ended 31st March, 2024	Restated consolidated figures for the year ended 31st March, 2023	Restated consolidated figures for the year ended 31st March, 2022
Gross amount required to be spent by the company during the year. Gross amount spent by the company during the year. Shortfall/(Excess)	4.86 6.06 (1.20)		

a. Disclosure on natue of CSR activities undertaken by the companies

Porticulare	Restated consolidated figures for the year ended 31st March, 2024					
Particulars	Paid in cash	Paid via bank	Paid in kind	Payble	Total	
Promoting education	-	6.06	-	-	6.06	

Particulars	Restated consolidated figures for the year ended 31st March, 2023					
Particulars	Paid in cash	Paid via bank	Paid in kind	Payble	Total	
Promoting education	-	-	-	-	-	

Particulars	Restated consolidated figures for the year ended 31st March, 2022					
Particulars	Paid in cash	Paid via bank	Paid in kind	Payble	Total	
Promoting education	-	-	-	-	-	

2.Material Adjustments :

The Summary of results of restatement made in the Audited Financial Statements for the respective years and its impact on the profit/(loss) of the Company is as follows:

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022
(A) Net Profits After Tax as per audited financial statements	1,627.63	336.81	(110.90)
Add/(Less) : Adjustments on account of -			
1) Prepaid Expenses of P.Y. Transfer to Expenses	· · ·		
2) Prepaid Expenses and Disallowance Exp. of current Year	-	-	
3) Provision for Outstanding Expenses Payable			
4) Difference on Account of Calculation in Deferred Tax			
5) Change in Provision for Current Tax			-
6) Change in Provision of Depreciation		· · · ·	
7) Change in Provision of Gratuity			
8) Change in Provision of Audit Fees			-
Total Adjustments (B)	1		-
Restated Profit/ (Loss) (A+B)	1,627.63	336.81	(110.90)

Reconciliation Statement between Restated Reserve & Surplus affecting Equity due to Adjustment made in Restated Financial Statements:

Particulars	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023	Restated consolidated figures as at the end of 31st March, 2022
Equity Share Capital & Reserves & Surplus as per Audited financial Statement	4,109.07	2,729.89	2,393.08
Add/(Less) Adjustments on account of change in Profit/Loss Total Adjustments			
Equity Share Capital & Reserves & Surplus as per Restated Financial Statement	4,109.07	2,729.89	2,393.08

Restated statement of capitalisation

Particulars	Pre Issue	Post Issue	
Debts			
A. Long Term Debt*	1,803.16	1,803.16	
B. Short Term Debt*	2,398.11	2,398.11	
C. Total Debt	4,201.27	4,201.27	
D. Equity Shareholders Funds			
Equity Share Capital	2,000.00	[•]	
Reserves and Surplus	2,109.07	[•]	
Total Equity(D)	4,109.07		
Long Term Debt/ Equity Ratio (A/D)	0.44	[•]	
Total Debt/ Equity Ratio (C/D)	1.02	14 10	

a

*

Lucknow

per our report of even date attached M/s Msnu& Associates LLP Fo ountants Cł b a ter on no. :- 018542C/C400322 regi tra

tit tagi Navquit Partner

Membership no. :- 533375 UDIN no. :- 24533375BKFJMP1629 Place :- Noida Date :- 12-09-2024

Chanc ASSOCIATES LLO * 018542C/C400322 * CHARTERED ACCOUNT

Director Amar singh Managing director Din. :- 01096328 Place :- Lucknow cknow

Réjeev nain O. ROPO'& Company secretary CFO Place:r-12-09-2024 Space:-Lucknow

*

For & on behalf of the board of directors Chandan Healthcare Limited Anut Imited Director Asmita Singh Managing director Din. :- 01098055 * * Place :- Lucknow //Cknow Date :- 12-09-2024

ealthc

